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ABSTRACT 
 Cerium oxide nanoparticles (CeO2 NPs)(nanoceria) have been shown to possess a 
substantial oxygen storage capacity via the interchangeable surface reduction and oxidation of 
cerium atoms, cycling between the Ce4+ and Ce3+ redox states. Reduction of Ce4+ to Ce3+ causes 
oxygen vacancies or defects on the surface of the crystalline lattice structure of the particles, 
generating a cage for redox reactions to occur. The study of the chemical and biological 
properties of CeO2 NPs has expanded recently, and the methods used to synthesize these 
materials are also quite diverse. This has led to a plethora of studies describing various 
preparations of CeO2 NPs for potential use in both industry and for biomedical research. Our 
own work has centered on studies that measure the ability of water-based CeO2 NPs materials 
to reduce reactive oxygen and nitrogen species in biological systems, and correlating changes in 
surface chemistry and charge to the catalytic nature of the particles. The application in 
experimental and biomedical research of CeO2 NPs began with the discovery that water-based 
cerium oxide nanoparticles could act as superoxide dismutase mimetics followed by their ability 
to reduce hydrogen dioxide similar to catalase. While their ROS scavenging ability was well 
established, their ability to interact with specific RNS species, specifically nitric oxide (·NO) or 
peroxynitrite (ONOO-) was not known. The studies described in this dissertation focus on the 
study of RNS and cerium oxide nanoparticles. 
Our in vitro work revealed that CeO2 NPs that have higher levels of reduced cerium sites 
(3+) at the surface (which are effective SOD mimetics) are also capable of accelerating the 
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decay of peroxynitrite in vitro.  In contrast, CeO2 NPs that have fewer reduced cerium sites at 
the particle surface (which also exhibit better catalase mimetic activity) have ·NO scavenging 
capabilities as well as some reactivity with peroxynitrite. Our studies and many others have 
shown cerium oxide nanoparticles can reduce ROS and RNS in cell culture or animal models. 
The accumulation of ROS and RNS is a common feature of many diseases including Alzheimer’s 
disease (AD). Testing our CeO2 NPS in cortical neurons, we used addition of Aβ peptide as an AD 
model system. CeO2 NPs delayed Aβ-induced mitochondrial fragmentation and neuronal cell 
death. When mitochondrial ROS levels are increased, mitochondrial fission is activated by DRP1 
S616 phosphorylation. Specifically, our studies showed the reduction of phosphorylated DRP1 
S616 in the presence of CeO2 NPs. Results from our studies have begun to unravel the molecule 
mechanism behind the catalytic nature of how CeO2 NPs reduce ROS/RNS in biological systems 
and represents an important step forward to test the potential neuroprotective effects of CeO2 
NPs in model systems of AD. 
A plethora of studies describing various preparations of CeO2 NPs for potential use in 
both industry and for biomedical research have been described in the past five years. It has 
become apparent that the outcomes of CeO2 NPs exposure can vary as much as the synthesis 
methods and cell types tested. In an effort to understand the disparity in reports describing the 
toxicity or protective effects of exposure to CeO2 NPs, we compared CeO2 NPs synthesized by 
three different methods; H2O2 (CNP1), NH4OH (CNP2) or hexamethylenetetramine (HMT-CNP1). 
Exposure to HMT-CNP1 led to reduced metabolic activity (MTT) at a 10-fold lower 
concentration than CNP1 or CNP2 and surprisingly, exposure to HMT-CNP1 led to substantial 
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decreases in the ATP levels. Mechanistic studies revealed that HMT-CNP1 and CNP2 exhibited 
robust ATPase (phosphatase) activity, whereas CNP1 lacked ATPase activity. HMT-CNP1 were 
taken up into HUVECs far more efficiently than the other preparations of CeO2 NPs. Taken 
together, these results suggest the combination of increased uptake and ATPase activity of 
HMT-CNP1 may underlie the mechanism of the toxicity of this preparation of CeO2 NPs, and 
may suggest ATPase activity should be considered when synthesizing CeO2 NPs for use in 
biomedical applications.  
Overall the studies have uncovered two new catalytic activities for water-based CeO2 
NPs (·NO scavenging and accelerated decay of peroxynitrite), demonstrated their ability to 
reduce RNS in an AD cell culture model as well as identifying a catalytic activity (phosphatase) 
that may underlie the observed toxicity of CeO2 NPs reported in other studies.  
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CHAPTER 1: INTRODUCTION 
Aging 
Progressive accumulation of damaged molecules or tissues are associated with aging 
and are believed to be responsible for the ever-increasing susceptibility to disease and death 
(1). In 1956, Harman proposed the ‘free radical theory of aging’ (2) which implicated increasing 
levels of oxidatively damaged biomolecules is due to the formation of reactive oxygen species. 
These reactive species including free radicals (i.e. superoxide, hydroxyl, carbonate) lead to 
deleterious side effects on most cell constituents (2). Reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) are reactive molecules that can damage all types of 
biomolecules, including DNA, proteins, and lipids with the formation of toxic and mutagenic 
products. ROS/RNS can originate from exogenous sources such as ultraviolet light (UV), ionizing 
radiation, and other environmental stress or they can be generated intracellularly as a 
consequence of normal metabolism (3). Aerobic organisms possess antioxidant enzymes (i.e. 
superoxide dismutase, catalase, peroxiredoxins), antioxidants (i.e. glutathione, uric acid) and 
mis-folded protein degradation defense systems that deal with ROS produced as a consequence 
of aerobic respiration and oxidation of biomolecules (4). Macrophages of the immune system 
can create ROS by deliberately producing superoxide to rid itself of foreign material such as 
bacteria and viruses (5). Mammalian cells and tissues can tolerate certain levels of these 
species, but excessive levels of ROS leads to damage to cells and tissues (6). Life expectancy has 
also been shown to decline with an increase in the generation of ROS in many species (7). In 
addition to the normal levels of oxidative stress formed during regular metabolism, 
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neurodegenerative disease models have suggested that cells may also be subjected to damage 
by RNS resulting from elevated levels of nitric oxide (·NO) and its reactive intermediate 
compounds, including peroxynitrite (ONOO-) (8). The pathogenesis of diseases including many 
degenerative diseases involve the generation of ROS and RNS associated with mitochondrial 
dysfunction (9). Exposure to pesticides, toxins and other exogenous factors as well as 
endogenous factors may trigger the over-production of ROS and RNS (10). For organisms to 
withstand this imbalance and prevent or diminish ROS and RNS induced damage, it is important 
to evaluate new modes of therapy and treatment.  
Antioxidants 
Decreasing the levels of ROS and RNS is the role many antioxidant molecules play. 
Cellular protective effects of antioxidants have been extensively studied and have 
demonstrated their ability to directly scavenge ROS/RNS or their precursor molecules by 
attenuating the catalysis of ROS/RNS generation in most instances using metal dependent 
coenzymes (11). Effectively managing diseases is the foremost goal in medical research today 
and many studies have used therapeutic antioxidants in their research which did not have 
satisfactory pharmacological outcomes. In recent human studies, several antioxidants including 
β-carotene, vitamins C and E, NAC (12), coenzyme Q10  (13) and tetra-hydrocurcumin have been 
shown to provide protective effects in cellular and animal models of AD (14). However, their 
efficacy in human trials provided at best only modest changes in disease progression (12, 15, 
16). Among the problems are their poor stability and repetitive dosing, underscoring the need 
for alternative strategies.  
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Treatment efficacy of diseases that respond to antioxidants should be improved by 
using catalytic antioxidants, which would then decrease the need for repetitive dosing. This 
would allow the breakdown of toxic molecules without the catalytic antioxidants themselves 
becoming inactivated (11). It has become apparent that identifying compounds for treating the 
excessive formation of ROS and RNS in diseases without interfering with normal metabolism or 
resulting in additional adverse effects is an important standard (17).  
Nitric Oxide 
The role of ROS and its effect on aging has received considerable attention since Dr. 
Harman first proposed the ‘free radical theory of aging.’ More recently, the role of RNS have 
been shown to have a direct role in cell signaling, vasodilatation and the immune response (18). 
Nitrosative stress, defined by the excessive production of reactive nitrogen species, causes 
damage to macromolecules and can lead to degenerative diseases, contribute to metabolic 
diseases and if in great excess can lead to cell death through a variety of molecular 
mechanisms. The role that RNS play in many age related diseases is now just being appreciated. 
Nitric oxide has many physiological functions (neurotransmitter, blood vessel dilation) 
but also ·NO can convert into a highly reactive and toxic molecule, peroxynitrite, that readily 
reacts with proteins, DNA, and lipids to alter their function (19). Nitric oxide reacts with various 
molecules in vitro and in vivo and the products of these reactions can damage the cell through a 
variety of mechanisms. One mechanism, S-nitrosylation is a post-translational, redox-related 
modification of cysteine thiols by nitric oxide (20). Additionally, tyrosine residues can be 
modified to generate 3-nitrotyrosine, and subsequently this modified amino acid is used as a 
4 
 
biomarker of nitric oxide -related oxidants (21). Accumulating evidence suggests that the 
specific proteins are regulated through S-nitrosylation and tyrosine nitration, and these sites 
play key roles in human health and disease. S-nitrosylation is a reversible reaction, often tied to 
regulation of enzyme activity (22-24) whereas and 3-nitro tyrosine is a stable covalent adduct 
(25). Nitric oxide, if present in excess of antioxidant defense systems, can trigger nitrosative 
damage to macromolecules through its reactive intermediates, which in turn may contribute to 
degenerative diseases due to various reasons including the structural alteration of proteins, 
inhibition of enzymatic activity, and interferences of the regulatory function (18).  
Peroxynitrite 
A primary reaction in the production of RNS is the diffusion limited reaction of ·NO and 
superoxide radical (O2
-·) to form ONOO- (26). ONOO- is a powerful oxidant and has been shown 
to react with all classes of biomolecules including thiols (27), lipids (28), carbohydrates (29) and 
DNA (30). The oxidative chemistry of peroxynitrite in biological systems depends upon the 
availability of targets (31), but the primary deleterious effect of ONOO- is the inactivation of 
enzymes (32). Modification of amino acid residues on the active site of key proteins may result 
in detrimental change in function of the proteins. Tyrosine nitration of proteins has become an 
important marker for inflammation and for nitrosative stress and has been detected in a 
number of diseases and pathological conditions (33). Likewise, disproportionate amounts of 
nitric oxide can compete with oxygen causing the interruption of electrons from the respiratory 
chain which results in increased formation of O2
•-  (33) and thus increased peroxynitrite leading 
to the post-translational modification of proteins. Tyrosine nitration occurs with the 
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incorporation of a nitro group (-NO2) at position 3 of the aromatic ring of tyrosine and  the 
majority of nitration  is due to the simultaneous availability of a tyrosyl radical (Tyr·) and 
nitrogen dioxide  radical (·NO2) (34). Addition of a -NO2 group to tyrosine can alter protein 
function by various modes including lowering the pKa of its phenolic –OH.  This bulky 
substituent which if placed on a relevant tyrosine, can alter protein function and conformation, 
impose steric restrictions, and also inhibit tyrosine phosphorylation. (35). 
 Several specific proteins and systems have been shown to be modified by ONOO- . 
Peroxynitrite has been shown to cause tyrosine nitration of complex I of the respiratory chain 
thus effecting mitochondrial injury (36). Increased levels of nitrated proteins have been 
reported in AD brains as well as cerebrospinal fluid in patients with AD (37). Several proteins 
present in AD have been shown to be nitrated by peroxynitrite (33). Peroxisome proliferator-
activated receptor gamma (PPARγ) expression protects neurons from Aβ- mediated toxicity (38) 
however its nitration prevents its translocation to the nucleus, thereby preventing 
mitochondrial biogenesis (39). Protection against peroxynitrite damage in vivo is provided by 
several antioxidants (40) as well as eliminated by many of the anti-oxidant enzymes, 
peroxiredoxins (41).  The rate of reduction of peroxynitrite by ascorbate (42), glutathione (43) , 
and uric acid (44) is too slow during the course of disease or increased nitrative stress to 
prevent damage (45).  Effective antioxidants that can selectively quench ROS/RNS species such 
as peroxynitrite or superoxide and provide lasting effects are needed. Finding a specific ONOO- 
scavenger is of considerable importance.  
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Manganese (Mn) Porphryins 
Aerobic organisms evolved antioxidant defense systems that deal with ROS produced as 
a consequence of aerobic respiration (4). Superoxide dismutase (SOD) developed as a defense 
mechanism against oxidative stress to more rapidly convert O2
·- to H2O2 (46), even though the 
spontaneous reaction with protons is nearly as effective as the enzyme catalyzed reaction.  H2O2 
is then acted upon by catalase, glutathione peroxidase and/or peroxiredoxins to maintain a 
healthy level of peroxide in cells and tissues. These endogenous enzymes work in concert to 
limit ROS, and their synthesis and expression is generally tissue and cell type specific. SOD 
belongs to a diverse group of enzymes that have metal ions which are usually coordinated by 
nitrogen, oxygen or sulfur centers, to assist in the process of electron transfers (47)  called 
metalloenzymes. Since its discovery many chemists and biochemists have developed 
synthetically produced metal based small molecule catalysts to try and mimic the active site of 
SOD. These so called SOD mimics have been shown to increase the lifespan of nematodes (48) 
and  a number of studies have shown their ability to scavenge O2
·- and/or H2O2 utilizing various 
metalloprophyrin motifs (49-51). 
Cerium Oxide Nanoparticles 
The use of CeO2 nanoparticles (NP) for potential therapy in cancer, age-related and 
neurodegenerative diseases represents a novel strategy for a unique technology. Cerium is a 
rare-earth element belonging to the lanthanide series. In bulk, CeO2 is in the 4+ oxidation state. 
Cerium is distinctive in that in its oxide nanoparticle form, the cerium atom can exist in either 
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3+ (fully reduced) or 4+ (fully oxidized) and may interchange between the two states (52).  Babu 
et al (53) have synthesized CeO2 NPs that vary in the amount of 3+ and 4+. The oxidation state 
can be represented by CeO2-x. Cerium oxide also contains oxygen vacancies or “defects” in the 
lattice structure caused by loss of oxygen and/or its electrons (54).  CeO2 NPs have similar 
chemical and physical properties to bulk cerium but due to the increased surface area to 
volume ratio, along with oxygen vacancies, CeO2 NPs have the potential as a unique catalyst 
(55) and can act as a free radical scavenger or antioxidant. The valence and defect structure of 
cerium oxide is therefore dynamic and may change spontaneously or in response to physical or 
biological parameters (56). Preliminary biocompatibility testing has shown no toxicity or other 
adverse reactions to CeO2 NPs in the eyes of rats (57). Further work from this group 
demonstrated CeO2 NPs additionally extend photoreceptor cell lifespan in tubby mice by 
modulation of apoptosis/survival signaling pathways by slowing the progression of retinal 
degeneration.  The protective effect by CeO2 NPs was demonstrated by decreasing ROS, down-
regulating apoptosis signaling pathways and upregulating the expression of neuroprotection-
associated genes resulting in slowing of photoreceptor degeneration (58). Treatment with CeO2 
NPs reduced total nitrated proteins in transgenic MCP-1 mice using CeO2 NPs in the Ce
4+ state 
(59). Continuing work from this lab indicate that CeO2 NPs can inhibit the ROS induced by 
cigarette smoke extract in cardiomyocytes (60). Interestingly, the CeO2 NPs used in this second 
study contained an increased concentration of Ce3+ on their surface. Elevated ROS from chronic 
cigarette exposure can result in cardiomyopathy and may also activate nuclear factor-kB (NF-
kB), a redox-sensitive transcription factor. CeO2 NPs were able to inhibit this activation. The 
reactivity of the cerium atoms at the surface of CeO2 NPs is critical to their catalytic properties 
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and reactivity is reflected in their Ce3+/Ce4+ ratio. These studies approach the on-going issue of 
what happens to the oxidation state of the CeO2 NPs once they are inside cells or animals and 
suggests that CeO2 NPs may indeed act as regenerating catalytic antioxidants. Exploring the 
surface properties and catalytic abilities of CeO2 NPs to scavenge free radicals in vitro and in 
vivo will aid in the search for future effective therapies for management of diseases where 
radicals have been proposed to play a role. 
Numerous synthetic catalytic scavengers of ROS and RNS have been made and tested in 
various model systems. Copious metalloporphyrins have been synthesized to have high 
reactivity with O2
·-, H2O2, ·NO and ONOO
- (8, 50, 61, 62). Most studies affirm metalloprophyrins 
are useful tools for researching and understanding the roles that ROS and RNS may play in 
diseases, however, their potential toxicity due to metals has often come into question for their 
use humans. The health effects of CeO2 NPs are not as yet well understood and there are 
reports which claim that CeO2 NPs are both protective and toxic (63-66). In considering CeO2 
NPs as potential therapeutic agents it is important to pay attention to their synthesis method, 
concentration, and surface chemistry. The preparation/synthesis methods of CeO2 NPs result in 
particles with a wide variety of surface functionalities and modifications, and these properties 
will dictate whether a nanoparticle will be protective or deleterious. There are well established 
synthesis methods in which CeO2 NPs are consistently shown to exhibit SOD mimetic activity 
(55, 56) , catalase mimetic activity (67) or NO scavenging abilities (68) whereas other synthesis 
methods result in CeO2 NPs without comparable antioxidant properties (66). Thus these factors 
as well as concentrations used and cell type studied might account for the seemingly conflicting 
reports.  
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Alzheimer's Disease 
Alzheimer’s Disease (AD) is among the most common neurodegenerative disorders. AD 
is a progressive and irreversible disorder of the central nervous system that confers an 
enormous economic as well as emotional burden on patients, caregivers and society (69). 
Reactive oxygen species (ROS) and RNS are formed during normal metabolism but an imbalance 
may result from the increase production of free radicals or from the failure of antioxidants and 
antioxidant enzymes to adequately scavenge the damaging molecules. This imbalance has been 
documented to be involved in AD (70).  
The mechanism of how ONOO- promotes neurotoxic effects is still being elucidated but 
mitochondrial injury seems to be a primary cause (71, 72) due to ONOO- ability to oxidize or 
nitrate all biomolecules. Strong evidence suggests that mitochondrial dysfunction is an early 
event in AD (73). Among the reported changes are altered morphology and ultrastructure of 
mitochondria, inhibition of respiration and ATP production, and increased ROS production (74). 
However, what causes the failure in mitochondrial function is unclear.  
Widespread ONOO- mediated damage is seen in brain tissue from AD in the form of 
increase protein nitration in neurons (75). This increase in nitration, the result of increased 
nitrosative stress, has been attributed to the aggregation of the Aβ peptide into amyloid 
plaques, one of the defining morphological features of AD (76). The molecular basis of this 
increase of Aβ-induced RNS has been shown to be an impaired synaptic transmission, 
specifically the modulating of NMDA-type glutamate receptors (77). In addition, AD pathology is 
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also characterized by self-assembly of the tau protein into neurofibrillary tangle (NFT). Tyrosine 
nitration of the tau proteins has been demonstrated in many studies (78, 79) further implicating 
ONOO- in AD.  
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CHAPTER 2: CERIUM OXIDE NANOPARTICLES Ce3+ RATIO DETERMINES 
REACTIVITY TOWARDS NITRIC OXIDE RADICAL (·NO) AND PEROXYNITRITE 
(ONOO-) 
Introduction 
The study of the chemical and biological properties of CeO2 NPs has expanded recently. 
However, most of the focus has been on the ability of these materials to reduce reactive oxygen 
(ROS). CeO2 NPs have been shown to protect several cell types and animal models against ROS 
mediated diseases (80) with little study of their effect on specific reactive nitrogen species 
(RNS). In these studies, we have obtained evidence that cerium oxide nanoparticles (CeO2 NPs) 
are able to interact with two very important nitrogen species, nitric oxide radical (·NO) and 
peroxynitrite (ONOO-). For the scavenging of ·NO, this activity is present in CeO2 NPs with a 
lower level of cerium in the 3+ state (CeO2 NPs with low 3+/4+ ratio (CNP2) and therefore a 
reduced number of oxygen vacancies), in contrast to the superoxide scavenging properties 
which are correlated with an increased level of cerium in the 3+ state (CeO2 NPs with high 
3+/4+ ratio (CNP1) and therefore an increased number of oxygen vacancies). In the case of 
peroxynitrite, CNP1 and CNP2 share the catalytic ability of reducing the effect of peroxynitrite, 
though to different degrees.   
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Materials and Methods 
Nanoparticle Synthesis and Characterization  
The cerium oxide nanoparticles were synthesized by wet chemical process as previously 
described (81). Chemicals for CeO2 nanoparticle synthesis, Ce (NO3)3, H2O2, were obtained from 
Sigma-Aldrich (St. Louis, MO). In brief, to prepare CNP1 with a high ratio of Ce3+/ Ce4+, Ce 
(NO3)3 ∙ 6H2O (5 mM) was dissolved in dH2O and the nitrate precursor was stirred for 15 min 
then H2O2 (2% v/v) was rapidly added while stirring at 300 rpm. The solution was continuously 
stirred for 1 h to obtain a stable dispersion of cerium oxide nanoparticles.  Samples were stored 
at room temperature. All preparations were sonicated to ensure single nanoparticles (Branson, 
Danbury, CT) for 45-60 min prior use. CNP2 was synthesized using ammonium hydroxide 
NH4OH precipitation method. Briefly, cerium nitrate hexahydrate was dissolved in deionized 
sterile water and stoichiometric amount of NH4OHwas added and stirred for 4 h at room 
temperature. Cerium oxide nanoparticles were separated by centrifugation at 8000 g for 10 
min. SiO2 nanoparticles were purchased from Corpuscular Inc. (Cold Spring, NY). The surface 
chemistry of the cerium oxide nanoparticles was studied using a Physical Electronics (5400 PHI 
ESCA) spectrometer with a monochromatic Al Kα X-ray source operated at 300 W and base 
pressure of 1 ×10-9 Torr. The binding energy of the Au (4f7/2) at 84.0±0.1 eV was used to 
calibrate the binding energy scale of the spectrometer. 
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Assay for Nitric Oxide 
A ferrous hemoglobin assay was adapted from Murphy & Noack (82) in which ferrous 
hemoglobin (Hb) (Sigma-Aldrich) and ·NO react to form oxidized ferric hemoglobin. S-nitroso-N-
acetylpenicillamine (SNAP) (Molecular Probes), was used to generate ∙NO. Briefly, 200 μM of 
SNAP was added to 25 mg/mL ferrous Hb in the presence or absence of nanoparticles or the 
spin-trap DEPMPO (Enzo Life Sciences) in 100 mM phosphate buffer (pH 7.0). The oxidation of 
Hb was monitored using a Hewlett-Packard 8453 diode array spectrophotometer. We followed 
changes to spectra at wavelengths of 411 nm (isosbestic point) and 421 nm. The change in 
absorbance per unit time was measured for 10 min at 30 s intervals. The concentration of ·NO 
reacting with Hb was obtained by the difference in absorbance between 401-421 nm using an 
extinction coefficient of 77 mM-1cm-1  (82).  
Surface Chemistry Alteration by Phosphate Ions 
Phosphate buffer was prepared by dissolving monosodium phosphate (13.8 g/L) and its 
conjugate base, disodium phosphate (14.1 g/L), in 1 L of water to give a 0.1 M solution, and the 
pH was adjusted by titration with 1 M HCl to reach a pH value of 7.4. Water dispersed CeO2 NPs 
with higher levels of oxygen vacancies at their surface (200 μM) were suspended in equimolar 
phosphate buffer (pH 7.4) for 24 h at room temperature. The UV-visible spectra were recorded 
to determine surface chemistry of cerium using a UV-viable Hewlett-Packard 8453 diode array 
spectrophotometer in a 1.0 cm path length quartz cuvette.  
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·NO Detection Using Copper-fluorescein Method 
To measure ·NO by an alternate method we followed ·NO levels using a copper-
fluorescein (Cu-FL) probe as previously described (83). In these experiments, 100 μM of the ·NO 
generator, diethylamine NONOate diethylammonium salt (DEA/NO) (Sigma) was added to CuFL 
probe (1 μM) (Strum Chemicals, Newburyport, MA). Fluorescence was followed at an emission 
wavelength of 530 nm using an excitation wavelength of 503 nm in 50 mM sodium phosphate 
buffer, pH 7.0, containing 20 μM DPTA using a Varian Cary Eclipse fluorescence 
spectrophotometer (Palo Alto, CA) for 20 min at room temperature. Assays were carried out in 
the presence or absence of CeO2 NP, SiO2 NPs or glutathione (Fisher Scientific, Pittsburg, PA).  
Zeta Potential (ZP) and Particle Size Measurement 
Water dispersed CeO2 NPs with different 3+/4+ ratios were suspended in buffers 
according to the various conditions used in these studies and ZP and particle size measured. For 
surface chemistry alteration experiments, NPs were incubated for 24 h followed by ZP and 
particle size measurements using Zeta sizer (Nano-ZS) from Malvern Instruments. 
Peroxynitrite Decay Using Spectroscopy  
Peroxynitrite (20 μM) was added under stirring into a 1 ml quartz cuvette with a 1 cm 
path length. Each sample was analyzed for a total of 600 seconds with a cycle time of 0.5 
seconds at a wavelength of 302 nm in 100 mM sodium or potassium phosphate buffers, pH 8.0, 
and 100 μM diethylenetriaminepentaacetic acid (DPTA) to minimize any potential interference 
by adventitious metal ions using a Hewlett-Packard diode array UV-visible 8453 
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spectrophotometer. Absorbance was normalized by subtracting the final absorbance from 
initial absorbance and dividing by the amplitude. 
Peroxynitrite Decay Using APF in vitro 
To measure the effects of nanoceria (100 μM), Glutathione (0.5 mM) or uric acid (1 mM) 
on the decay of peroxynitrite (20 μM), APF (10 μM) fluorescence was measured at 
excitation/emission wavelengths of 490 nm/515 nm in 0.1 mM sodium phosphate buffer, pH 
7.4, containing 100 μM DPTA using a Varian Cary Eclipse fluorescence spectrophotometer (Palo 
Alto, CA). We followed fluorescence for 1 min at room temperature using a quartz fluorometer 
cell (Starna Cells, Inc. Atascadero, CA). Peroxynitrite was added last due to the short-half of 
peroxynitrite at pH 7.4. End-point assays fluorescence was read after 10 min incubation using 
same buffer conditions as kinetic studies. As stock solutions of ONOO- contain 0.3 M NaOH, 
control incubations were performed with equivalent amounts of NaOH.   
Dot Blot Assay 
500 ng BSA treated with 10 μM peroxynitrite (ONOO-)(Cayman Chemicals)   in the 
absence and presence of 500 nM  NPs, 100 μM NPs or 1 mM GSH @ RT for 20 min .  
Nitrocellulose (Hybond ECL, GE Healthcare) was equilibrated using  1X TBS and placed in Hydri-
Dot manifold (BRL). Reactions were pipetted in to the membrane and allowed to incubate for 
20 min. After 3 washes, membrane was blocked in 5% milk, 1X TBS+0.1% Tween. Blot was 
probed with antibody specific for 3-nitro-tyrosine modification (Sigma #N0409) followed by 
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HRP-conjugated secondary (ECL). For detection, West Dura substrate (Thermo Scientific) was 
used as per protocol.  
Results  
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are normal 
byproducts of oxidative metabolism in mammals. If unchecked, they can cause damage to 
proteins, DNA, and lipids contributing to diseases ranging from atherosclerosis and aging to 
neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease. Nitric oxide radical 
(·NO) is a gaseous free radical which exhibits multifaceted biological effects, both beneficial and 
damaging. Nitric oxide functions as an important messenger molecule, as an essential 
neurotransmitter, (84) and regulator of cardiovascular physiology (85). ·NO is not particularly 
toxic in vivo, however, recent evidence indicates the cytotoxicity attributed to ·NO is due to 
formation of the potent oxidant peroxynitrite (ONOO-), formed by the diffusion limited 
interaction of superoxide (O2·
-) with ·NO (86). While neither ·NO nor O2·
- are strong oxidants, 
ONOO- is highly reactive and can oxidize DNA, proteins and lipids(34).  
Cerium oxide (CeO2) is a rare earth metal oxide catalyst known for its ability to remove 
carbon monoxide (CO), hydrocarbons and nitric oxide species (NOx) from exhaust gas (87) and is 
widely used as a catalyst in industrial applications because of its potent redox-active 
properties(88). The adsorption and reaction of ·NO on CeO2 has been shown to be influenced 
by the valence state of the surface cerium (89). and bulk CeO2 has been shown to adsorb ·NO 
only on reduced or partially reduced sites (90). Weakly absorbed ·NO on pure CeO2 at room 
temperature has been reported (91) as well as evidence for the transfer of the unpaired 
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electron from ·NO to Ce in the 4+ state (92). These catalytic studies have been performed in the 
absence of water and under non-biological conditions. Whether CeO2 NPs react with ·NO under 
physiologically relevant conditions has yet to be determined. Other redox active catalysts, 
especially manganese porphyrins, have been shown to interact with ·NO (8). In this first study 
we determined the reactivity of CeO2 NPs with ·NO under biologically relevant conditions. 
To study CeO2 NPs ability to react with ·NO, water-based CeO2 NPs with different 3+/4+ ratios 
were synthesized and characterized. High resolution transmission electron microscopy (HR-
TEM) as well UV-visible spectroscopy confirmed that the CNP1 and CNP2 used in ·NO studies 
were indicative of HR-TEM images and absorbance’s of CeO2 NPs as previously reported (68). 
The ratios of Ce3+/Ce4+ were determined by XPS and sizes ranged 3-8 nm (determined by TEM) 
for CNP1 and CNP2 (68).  
CNP2 Scavenge ·NO 
The reaction between ·NO and the oxygenated, ferrous form of Hb can be used as a 
sensitive means to measure dissolved ·NO. We used S-nitroso-N-acetylpenicillamine (SNAP) to 
generate ·NO and we followed the conversion of the ferrous form of Hb to the ferric form of Hb 
by ·NO (82). Addition of CNP1 with high 3+/4+ ratio (75% 3+) had no effect on ∙NO’s ability to 
oxidize Hb suggesting no interaction with these NPs (Figure 1A). However, the addition of CNP2 
with low 3+/4+ ratio (20% 3+) inhibited the ability of ·NO to oxidize Hb in a dose dependent 
manner (Figure 1B). This pattern was similar to that observed with the known ·NO scavenger 
DEPMPO (Figure 1C). This result suggests that CNP2 prevent ·NO from oxidizing Hb. 
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To elucidate the scavenging efficiency of CeO2 NPs, we additionally determined the amount of 
dissolved ·NO in the presence and absence of CeO2 NPs or DEPMPO translating the data 
obtained from Hb assay experiments. The concentration of ·NO was obtained by difference in 
absorbance 401-421 nm using an extinction coefficient of 77 mM-1cm-1 (82)(Figure 2A-C). We 
observed concentration-dependent decreases in ·NO in the presence of varying levels of 
Ce3+/Ce4+ ratio and were able to calculate the rates of radical formation in the presence or 
absence of the catalyst (Table 1). 
Scavenging of ·NO by CNP2 Confirmed Using Alternate Detection Method 
In order to corroborate the data obtained from the Hb assay, we used an alternate 
detection method to determine CeO2 NPs ability to react with ·NO. A derivatized copper-
fluorescein conjugate (Cu-FL) has been shown to be a specific detector of ·NO production (93) 
though not as sensitive as Hb assay. We followed fluorescence emission at 530 nm upon 
addition of 100 μM of the NONOate DEA/NO, another ∙NO donor, in the presence and absence 
of CeO2 NPs. The addition of CNP1 had no effect on the ability of dissolved ·NO to oxidize the 
Cu-FL probe (Figure 3A). When CNP2 were included, we observed that the NPs prevented the 
oxidation of the Cu-FL probe and the fluorescent signal was decreased in a dose dependent 
manner (Figure 3B). This reduction in fluorescent signal by CNP2 is similar in efficacy as 
glutathione, a known ·NO scavenger (Figure 3C). By contrast, silicon oxide (SiO2) control NPs of 
similar size, were unable to prevent the ·NO-mediated Cu-FL oxidation (Figure 3D) suggesting 
that the changes in dissolved ·NO are specific to CNP2. Collectively, these data elucidate a 
previously unidentified catalytic property for CeO2. 
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CNP1 Can Convert to ·NO Scavenging Catalyst Upon Incubation with Phosphate. 
Recently, we have shown that incubation of CeO2 NPs with phosphate ions can 
interconvert these particles between the two catalyst (SOD or catalase mimetic) states (94).  To 
determine whether this property also applies to ·NO scavenging, we incubated CNP1 with 
phosphate and followed the presence of cerium atoms in the 3+ state (Figure 4). The 
absorbance peak between 230-260 nm (consistent with CeO2 NPs with higher levels of oxygen 
vacancies) disappears after addition of phosphate (Figure 4A) as previously described (94). After 
this conversion, CeO2 NPs are now able to effectively scavenge ·NO (Figures 4B & C) indicating 
this surface chemistry ‘switch’ also correlates with ∙NO scavenging. 
Discussion 
In summary, this study establishes the ·NO scavenging capability of CNP2 - CeO2 NPs 
with low 3+/4+ ratio. ·NO can be both electrophilic or nucleophilic in nature (95). The nature of 
this heterogeneous catalysis is not yet fully understood. Yet one could envision a mechanism by 
which CeO2 NPs scavenge ·NO through formation of an electropositive nitrosyl ligand due to 
internal electron transfer from ·NO to a Ce4+ site: 
                                   ( 1 ) 
This mechanism has been found in various synthetic ferric porphyrin species (96) and 
manganese complexes (97). In vivo ·NO reacts with O2
·- to form ONOO-, a potent oxidant that 
can lead to 3-nitrotyrosine (3-NT) modification of tyrosine residues in proteins(34). 3-NT is 
frequently used as a biomarker for nitrosative stress. Recently, a reduction in 3-nitrotyrosine 
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levels in a neural brain slice model was observed after treatment with CeO2 NPs(98) and in a 
cardiovascular disease model(99). It is likely that the observed scavenging of ·NO in this study 
contributed to the protective effects seen in these studies. CeO2 NPs surface chemistry is just 
now starting to be described and understood in respect to their ability to ameliorate cellular 
damage caused by both oxidative (superoxide, hydrogen peroxide) and nitrosative (·NO and 
thus ONOO-) stress.  For CeO2 NPs to become a viable therapeutic, their material properties 
must be optimized and thoroughly understood. 
 Cerium Oxide Nanoparticles and Their Reactivity with ONOO- 
Peroxynitrite is formed from the reaction of nitric oxide radical (·NO) with superoxide 
(O2
•-). The biochemistry of ONOO- is vastly complicated due to the multiple reactions possible in 
the presence and absence of CO2, H
+ and metals during its decomposition (34, 100). 
Determining CeO2 NP ability to scavenge ONOO
- in vitro is imperative to begin to understanding 
it’s biological capabilities. We have begun to discern the reactivity of CNP1 and CNP2 with 
peroxynitrite using three different assays.  
Dependent on their 3+ or 4+ oxidation states, nanoceria exhibit either SOD or catalase 
activity (55, 56, 67). Recent reports suggested that nanoceria are able to reduce nitrosative 
stress in various cell types (98, 99, 101). However, the underlying mechanism of their 
nitrosative stress reducing activity remains unknown. Given their redox cycling properties, it is 
conceivable that nanoceria might scavenge peroxynitrite. To test this idea we employed a cell-
free system in vitro. Physical and chemical analysis of the nanoceria preparations used were 
21 
 
confirmed and the CNP1 3+ oxidation state, CNP2 4+ oxidation state as well as fluorite structure 
and cerium spectrum  were previously reported (CD&D under review,(67)).  
CNP1 Accelerates Decay of Peroxynitrite in a Cell-free System in vitro  
Peroxynitrite exhibits a strong absorbance at 302 nm, hence its rapid decay can be 
measured within seconds using spectroscopy (102) Exploiting these properties, we observed 
that nanoceria dramatically accelerated the normal decay rate of peroxynitrite and with similar 
efficacy as uric acid or glutathione, two well established  peroxynitrite scavengers (Figure 5A) 
(103). By contrast, silicon oxide (SiO2) nanoparticles of similar size had no effect on the half-life 
of peroxynitrite.. A second addition of  peroxynitrite after complete decay resulted in renewed 
nanoceria-mediated peroxynitrite decomposition (data not shown), indicating that nanoceria is 
acting as a catalyst in the reaction with peroxynitrite.   
Accelerated Decay of ONOO- by CNP1 Confirmed Using APF Dye 
To confirm the novel peroxynitrite-lowering properties of CNP1, we followed the 
oxidation of 3'-(p-aminophenyl) fluorescein (APF) by fluorescence spectrometry in vitro (Figure 
5B). APF has no fluorescence at baseline, but when oxidized by peroxynitrite it exhibits 
fluorescence (104). Using this probe, we observed that CNP1 prevented the oxidation of APF in 
vitro, similar to glutathione and uric acid (Figure 1B) (105). Again, silicon oxide nanoparticles 
were unable to prevent the peroxynitrite-mediated APF oxidation.  Collectively, these data 
illustrate a previously unknown catalytic property of CeO2 NPs, namely their ability to reduce 
peroxynitrite in vitro. 
22 
 
3-Nitrotyrosine Protein Modification Diminished in the Presence of CNP1 or CNP2 
3-Nitrotyrosine (3-NT), a specific marker of protein nitration by ONOO-, is an established 
marker for RNS damage  (106). CeO2 NPs can be synthesized with high or low ratios of 
Ce3+/Ce4+. Reduction of Ce4+ to Ce3+ causes oxygen vacancies or defects on the surface of the 
lattice structure, hence provides a platform for redox cycles to occur. Though the nanoparticles 
have measurable starting ratios, it is conceivable that due to redox interactions, the ratios 
would change in vivo. To compare how CNP1 and CNP2 may act in the presence of cellular 
components, we tested whether CNP1 and CNP2 would be able to reduce peroxynitrite-
induced protein tyrosine nitration using bovine serum albumin (BSA) as an in vitro model. When 
BSA was pre-incubated with CNP1 or CNP2 alongside peroxynitrite, they prevented the 3-NT 
modification by peroxynitrite in a dose dependent manner (Figures 6A and B).  These findings 
suggest that CNP1 and CNP2 are accelerating the decay of peroxynitrite in a manner that can 
prevent the modification of tyrosine residues.  
Discussion – Accelerated Decay of Peroxynitrite  
Using cell-free assays we provide evidence for the ability of CeO2 NPs to accelerate the 
decay of peroxynitrite. The changes observed in the presence of cerium oxide nanoparticles 
represents compelling yet preliminary evidence that these nanomaterials readily react with 
peroxynitrite, or one or more of its breakdown products.  The mechanism by which these 
materials can alter the catalytic decomposition of peroxynitrite has yet to be elucidated. Others 
have shown that thiols, metals and carbon dioxide are the most likely targets of peroxynitrite in 
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vivo (34). Assuming cerium oxide reacts directly with peroxynitrite (and not decay products 
such as carbonate radical), a putative scheme of one electron oxidation and reduction reactions 
is shown that could explain the acceleration of peroxynitrite decay (Equation 2).   
O2·- + ·NO  ONOO- + H+  [·OH + ·NO2] 
(34)   ( 2 ) 
Ce3+ + ·NO2  Ce
4+ + NO2
-  ( 3 ) 
Ce3+ + ·OH  Ce4+ + OH-   ( 4 ) 
Ce3+ + O2·-   Ce4+ + O2
2-  ( 5 ) 
2Ce4+ + O2
2-  O2 + 2Ce
3+  ( 6 ) 
The proton-dependent decay of peroxynitrite results in production of nitrogen dioxide 
(Equation 3) radical and hydroxyl radical (Equation 4). Each of these potent radicals, which are 
one-electron oxidants, could react with cerium oxide nanoparticles at the particle surface (in an 
oxygen vacancy) to oxidize Ce3+ to Ce4+ (Equations 5 and 6) with the concomitant release of 
hydroxyl ion or nitrite. In our UV-visible measurements an absorption peak near that of nitrite 
(229 nm) was observed that paralleled the decrease in peroxynitrite levels (data not shown). 
Superoxide, derived from the back reaction of peroxynitrite to nitric oxide and superoxide could 
also serve as an oxidant with the products reducing cerium in the oxygen vacancy both in vitro 
and in vivo, especially given the location of the particles in the vicinity of the mitochondria. 
Although quite speculative, this putative pathway is a starting point for studies to determine 
the intermediates and rate constants for the reaction of cerium oxide nanoparticles with 
peroxynitrite and/or its decay products.  
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Figures and Tables 
 
Figure 1: CNP2 - CeO2 NPs with low 3+/4+ ratio scavenge ·NO. 
Represented in all graphs: closed circles = 25 mg/mL Hb alone; open circles = 25 mg/mL Hb + 
200 μM SNAP. A) CNP1- CeO2 NPs with high 3+/4+ ratio. B) CNP2- CeO2 NPs with low 3+/4+ 
ratio. C) DEPMPO addition. CeO2 NPs or DEPMPO were added at the concentrations indicated. 
Graph is representative of 3 or more experiments. 
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Figure 2: Effective scavenging of ·NO by CeO2 NPs lacking surface oxygen vacancies. 
The concentration of ·NO in the presence or absence of CeO2 NPs was quantified using the 
extinction coefficient for reaction with ferrous Hb (82). Data are derived from experimental 
data shown in Figure1. Represented in all graphs: closed circles = 25 mg/mL Hb alone; open 
circles = 25 mg/mL Hb + 200 μM SNAP. A) CNP1- CeO2 NPs with higher levels of oxygen 
vacancies at their surface. B) CNP2- CeO2 NPs with reduced levels of oxygen vacancies. C) 
DEPMPO addition. CeO2 NPs or DEPMPO were added at the concentrations indicated. Graph is 
representative of 3 or more experiments. 
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Table 1: Changes in ·NO levels in the presence of CeO2 nanoparticles 
Reaction conditions NP conc. 
(µM) 
NO production ratea 
(pmol min-1 +/- SD 
SNAP (200 µM) control 0 51.6 ± 4.4 
SNAP + CNP2    50 42.1 ± 5.7 
100 25.8 ± 2.9 
250 14.3 ± 3.3 
SNAP +  CNP1 250 52.5 ± 2.9 
SNAP + CNP1 + PO4 200 39.7 ± 5.9 
aRates are pmol min-1 and were calculated by determining the rate of change in absorbance per 
unit time, based on the molar extinction coefficient of conversion of HbO2 to metHb in the 
presence of ·NO (401 nm-421 nm) (Δε = 77 mM -1cm-1). SD = standard deviation 
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Figure 3: Scavenging of ·NO by CeO2 NPs confirmed using alternate detection method. 
Fluorescence emission was monitored at 530 nm upon excitation at 503 nm. Represented in all 
graphs; closed circles = 100 μM DEA/NO. A) CNP1 - CeO2 NPs with high 3+/4+ ratio. B) CNP2 - 
CeO2 NPs with low 3+/4+ ratio. C) GSH addition. D) SiO2 NPs addition. CeO2 NPs, GSH or SiO2 
NPs were added at concentrations indicated. Graph is representative of 3 or more experiments. 
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Figure 4: CNP1 - CeO2 NPs with high level of surface oxygen vacancies can convert to ·NO 
scavenging catalyst upon incubation with phosphate. 
A) CNP1 were incubated in 200 μM sodium phosphate buffer at RT for 24h. Solid line represents 
CNP1 - CeO2 NPs with higher levels of oxygen vacancies at their surface and dotted line 
represents sample incubated in phosphate. B) ·NO scavenging by CeO2 NPs after incubation in 
phosphate. C) Effective scavenging of ·NO by CNP1 after incubation in phosphate. Closed circles 
= 25 mg/mL Hb alone; open circles = 25 mg/mL Hb + 200 μM SNAP; closed triangles = 25 mg/mL 
Hb + 200 μM SNAP + 200 μM CNP1 - CeO2 high Ce
3+/PO4. Graph is representative of 3 or more 
experiments. 
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Figure 5: CNP1 scavenge peroxynitrite in vitro. 
(A) Relative absorbance of peroxynitrite (25 μM) at 320 nm over time (seconds) either in the 
absence or presence of CeO2 nanoparticles (100 μM), SiO2 nanoparticles (100 μM), uric acid 
(UA) (1mM), or glutathione (GSH) (0.5 mM) using spectrometry. (B) Relative APF (10 μM) 
fluorescence at 490 nm excitation and 515 nm emission wavelength of either peroxynitrite (20 
µm) alone, or in combination with CeO2 nanoparticles (100 μM), SiO2 nanoparticles (100 μM), 
uric acid (1mM), or glutathione (0.5 mM) measured over a time period of 14 seconds.  Data are 
representative of three or more experiments. 
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Figure 6: 3-nitrotyrosine protein modification diminished by CeO2 NPs. 
A) Graphical representation of BSA western blots protected from nitration with dose dependent 
addition of CeO2 NPs. B) Representative blots.  All lanes contain 500 ng BSA treated with 10 μM 
peroxynitrite (ONOO-) in the absence and presence of 500 nM NPs, 100 μM NPs or 1 mM GSH.  
Blots were probed with anti-3-nitrotyrosine antibody. Individual experiments were normalized 
to their individual BSA/ONOO- treated lane. Data are representative of three or more 
independent experiments. p ≤ 0.001. Statistics: Student’s t test. 
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CHAPTER 3: CERIUM OXIDE NANOPARTICLES DELAY Aβ-INDUCED 
MITOCHONDRIAL FRAGMENTATION AND NEURONAL CELL DEATH  
Introduction 
Nitric oxide (·NO) is an important neurotransmitter and neuromodulator normally 
required for learning and memory (84, 107). ·NO is generated by nitric oxide synthases (NOSs), 
a group of enzymes that produce ·NO from L-arginine in mammals. In addition to its role in 
normal physiology, ·NO is implicated in pathophysiology. When overproduced, ·NO combines 
with superoxide anions (O2
·-), byproducts of oxidative phosphorylation in mitochondria, to form 
peroxynitrite anions (ONOO-) which are highly reactive as well as neurotoxic and can oxidize 
DNA, proteins, lipids. The accumulation of  reactive oxygen species (ROS) and nitrogen species 
(RNS), also known as oxidative or nitrosative stress respectively, is a common feature of many 
diseases  including Alzheimer’s disease (AD) (84, 107). Excessive nitrosative stress in the 
nervous system can originate from glial cell activation and release of inflammatory cytokines. 
Alternatively, nitrosative stress can be caused by excessive accumulation of excitatory amino 
acids such as glutamate and N-methyl-D-aspartate (NMDA), which results in overstimulation of 
synaptic NMDA-type glutamate receptors, increased cytoplasmic Ca2+, neuronal NOS activation, 
and subsequent overproduction of ·NO/ONOO-.  
Excessive nitrosative stress causes neuronal damage and cell death by impinging on 
several cellular pathways. RNS can react with the cysteine or tyrosine residues of protein 
targets, altering their structure and/or function (84, 107). These protein modifications of S-
nitrosylation or nitration play a role in protein aggregation, a central hallmark of 
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neurodegenerative disorders. In AD nitrosative stress contributes to insoluble protein deposits 
of A and phosphorylated tau protein (84). Furthermore, nitrosative stress can activate 
signaling pathways and kinases, including Jun amino terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) (108-110). Moreover, nitrosative stress can induce 
mitochondrial fragmentation, resulting in mitochondrial dysfunction (111). 
Mitochondria are a source of free radicals. Disrupted energy metabolism from A 
resulting in inhibition of mitochondrial oxidative phosphorylation and respiration is implicated 
in AD. Normally an accumulation of ROS such as superoxide and H2O2 are neutralized by the 
enzymes superoxide dismutase 1 and 2 (SOD1, SOD2) and catalase. Peroxynitrite can inhibit 
complex I and IV of the mitochondrial respiratory chain, culminating in bioenergetic failure and 
a vicious cycle of ROS production (112, 113). When ROS detoxifying mechanisms fail or become 
overwhelmed, the event causes irreversible damage to biomolecules and can result in 
functional decline, characteristic of aging and age-related disorders (114).  
Neurons depend on mitochondrial energy production to fuel processes including 
synaptic transmission, ion pump and channel activity, and axonal and dendritic transport (111). 
Strong evidence suggests that mitochondrial dysfunction is an early event in AD (73). Among 
the reported changes are altered morphology and ultrastructure of mitochondria, inhibition of 
respiration and ATP production, and increased ROS production (74). However, what causes the 
failure in mitochondrial function is unclear. We recently postulated that the defects in 
mitochondrial function are caused by an imbalance in mitochondrial fission and fusion (71, 84, 
107, 111). Notably, peroxynitrite, generated by exogenous ·NO donors or neurotoxic insults like 
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NMDA or Ainduces mitochondrial fragmentation caused by activation of fission and/or 
inhibition of counterbalancing fusion (71, 75).  
To maintain their energy producing function, mitochondria must frequently divide and 
fuse. Evidence suggests that an imbalance in mitochondrial division and fusion plays a causal 
role in AD (115). Mitochondrial division and fusion is regulated by large GTPases of the dynamin 
family. Dynamin-related protein 1 (DRP1) is required for mitochondrial division. Inhibition of 
mitochondrial division by expression of the GTPase defective DRP1K38A mutant provides 
protection against excessive ·NO, NMDA, or A (71). The exact mechanism that accounts for the 
·NO-induced mitochondrial fragmentation remains unclear. A recent report suggested that S-
nitrosylation of DRP1 at cysteine 644 increases DRP1 activity and is the cause for the 
peroxynitrite-induced mitochondrial fragmentation in AD (107, 116). However, the work 
remains controversial, suggesting alternative pathways might be implicated (107, 117). 
Nitrosative stress causes rapid DRP1 Serine 616 (S616) phosphorylation, which promotes its 
translocation to mitochondria and organelle division (117, 118). In mitotic cells DRP1 S616 
phosphorylation is mediated by Cdk1/cyclinB1 and synchronizes mitochondrial division with cell 
division (119, 120). Interestingly, p-DRP1 S616 levels are markedly increased in brains of 
individuals with AD, suggesting that this event might contribute to the change in mitochondrial 
morphology and energy metabolism in AD (117, 119). The kinase responsible for DRP1 S616 
hyperphosphorylation in AD is unknown, but Cdk5/p25 is a potential candidate kinase 
mediating this process (75, 121). Notably, aberrant Cdk5/p25 signaling causes tau 
hyperphosphorylation in postmitotic neurons and is implicated in A-mediated 
neurodegeneration (119, 122-124).  
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While it is clear that nitrosative stress is at the heart of AD and other common age-
related disorders, effective antioxidants that can selectively quench ROS/RNS species such as 
superoxide, H2O2, ·NO and/or peroxynitrite and provide lasting effects are missing. Cerium (Ce) 
is a rare earth element and its oxide nanoparticle form uniquely exists in both 3+ and 4+ 
oxidation states.  Reduction of Ce4+ to Ce3+ causes oxygen vacancies or defects on the surface of 
the crystalline lattice structure of the particles, generating a cage for redox reactions to occur 
(125). Accordingly, nanoceria mimic the catalytic activities of the antioxidant enzymes SOD (55, 
126) and catalase (67) as well as scavenge dissolved ·NO (127). The specificity of the catalytic 
activities depends upon the ratio of Ce3+/Ce4+ (94, 127). Given these unique antioxidant 
properties, we hypothesized that nanoceria, specifically CNP1 with increased ratio of 
Ce3+/Ce4+, detoxify ROS/RNS and protect against A-induced DRP1 S616 
hyperphosphorylation, mitochondrial fragmentation and neuronal cell death. 
Materials and Methods 
Reagents 
EBSS (Earle’s Balanced Salt Solution), Hanks buffer, Glutamax, B-27® supplement, 
LipoFectamine2000®, and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, 
CA). Neurobasal medium and Dulbecco’s Modified Eagle’s Medium (DMEM) were purchased 
from Hyclone (Logan, UT). Poly-L-lysine, Hepes, glutamine, formaldehyde, N-acetyl-L-cysteine 
(NAC), anti-3-nitrotyrosine, N-methyl-D-aspartate (NMDA), Ponceau S reagent, Durcupan ACM, 
3-nitropropionic acid (3-NP), Aβ peptides and chemicals for cerium oxide nanoparticle synthesis 
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were obtained from Sigma-Aldrich (St. Louis, MO). Hoechst 33342, pluronic acid, 3'-(p-
aminophenyl) fluorescein (APF) (for cell culture) were purchased from Molecular Probes 
(Eugene, OR). PVDF membrane was purchased from Bio-Rad Laboratories (Hercules, CA). The 
DsRed2-Mito vector was obtained from Clontech (Mountain View, CA). Vector Shield was 
purchased from Vector Laboratories, Inc., (Burlingame, CA). T-Per protein extraction reagent 
was purchased from Pierce Biotechnology, Inc., (Rockford, IL). Peroxynitrite and 2-[6-(4-
aminophenoxy)-3-oxo-3H-xanthen-9-yl]-benzoic acid (APF) (for in vitro experiments) were 
purchased from Cayman Chemicals (Ann Arbor, MI). All reagents for transmission electron 
microscopy (TEM) were purchased from Ted Pella (Redding, CA). SiO2 nanoparticles were 
purchased from Corpuscular Inc. (Cold Spring, NY). In addition the following antibodies were 
used: monoclonal mouse-anti-DRP1 antibodies (clone 8/DLP1, BD Bioscience), rabbit polyclonal 
anti-p-DRP1 S616 antibodies (Cell Signaling), rabbit polyclonal 3-nitrotyrosine (Sigma), rabbit β-
actin antibody (Cell Signaling); sheep-anti-mouse IgG-HRP (GE Healthcare), donkey-anti-rabbit 
IgG-HRP (GE Healthcare), goat-anti-mouse AlexaFlour488 (Invitrogen),  goat-anti-rabbit 
AlexaFluor594 (Invitrogen). 
Primary Cortical Neurons  
Pure cortical neurons were isolated from Sprague-Dawley rat embryos (E18) as 
previously described (71, 128).  
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Mitochondrial Fragmentation and Neuronal Cell Death 
Neurons were grown on poly-Lysine coated glass cover slips as described before and 
transfected with DsRed2-Mito after 5 days in vitro (DIV) using Lipofectamine2000®. 3-NP was 
prepared as previously described (128). The Aβ peptides were preaggregated as described 
before (71). Cell death was induced with 3-NP (10 mM, 8 h), glutamate (150 μM, 6 h), NMDA 
(150 μM, 12 h) Aβ (10 μM, 6 h) at 11–14 DIV or with SNOC (100 μM, 3 h) at 8 DIV. After various 
time periods neurons were fixed using 3.7% formaldehyde and 5% sucrose in PBS for 20 min at 
37º C. Nuclei were labeled with Hoechst 33342 (1 μg/ml). Quantification of mitochondrial 
fragmentation and neuronal cell death was performed as described (129). Fluorescence 
microscopy and image acquisition of mitochondrial morphology was performed as previously 
described (130). 
Western Blotting  
To detect protein nitration, neurons were lysed using T-Per extraction reagent (Pierce) 
supplemented with Complete Protease Inhibitor Cocktail (Roche Applied Science, US). Protein 
concentrations were determined using the Bradford assay (Pierce Biotechnology, Inc., Rockford, 
IL). Proteins were separated by 4-20% SDS-PAGE gradient gels (Invitrogen) and transferred to 
PVDF membranes (0.2 µm, Bio-Rad).  Nonspecific protein binding was blocked by incubating the 
membranes with TBS (50 mM Tris-Cl, pH 8.0, 150 mM NaCl), 0.02% Tween20, and 5% nonfat 
milk for 3 hours at room temperature. The membranes were then probed with primary rabbit 
polyclonal antibodies for 3-nitrotyrosine (Sigma) (1:500) overnight at 4°C. After four washes (5 
min) of TBS (0.02% Tween20), membranes were incubated for two hours at room temperature 
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with anti-rabbit horseradish peroxidase-conjugated secondary antibodies (GE Healthcare) (1: 
15,000) in blocking solution. After four washes (5 min) of TBS (0.02% Tween20), 
immunocomplexes were detected using the Super-Signal West-Dura chemiluminescence 
substrates (Pierce, Thermo Scientific, Rockford, IL). Restore Western Blot Stripping Buffer 
(Thermo-Scientific) was used to strip blots. Membranes were successively probed with anti-β-
actin antibody (Cell Signaling, 1:1000).  To measure the levels of p-DRP1 S616, neurons were 
lysed in buffer containing 50 mM Tris-Cl, pH 7.0, 150 mM NaCl, 1 mM MgCl2, 1 mM NaF, 1 mM 
NaVO4, 1 % NP40, 10 % glycerol and complete Protease Inhibitor Cocktail Tablets (Roche 
Applied Science, US). Membranes were blocked with 5 % nonfat milk in TBS (pH 8.0) with 0.05% 
Tween20 for 3 h at room temperature (RT) and were incubated with primary rabbit polyclonal 
antibodies for p-DRP1 S616 (Cell Signaling) (1:1000) overnight at 4°C. The membranes were 
then washed four times (5 min) with TBS (0.05% Tween) and incubated for 2h at room 
temperature with anti-rabbit horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare)(1:15,000) in blocking solution. After 4 washes (5 min) of TBS (0.05% Tween), 
immunocomplexes were then detected using the Super-Signal West-Dura or Femto 
chemiluminescent substrates (Pierce, Thermoscientific, Rockfod, IL). For reprobing the 
membranes were stripped with Restore Western Blot Stripping Buffer (Thermo-Scientific) 
according to the manufacturer and incubated with mouse monoclonal antibodies for DRP1 (BD 
Biosciences, clone 8/DLP1) (1:1000) antibody or with polyclonal rabbit antibodies for β-actin 
(Cell Signaling) (1:1000). 
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Immunocytochemistry for 3-nitrotyrosine 
For immunocytochemistry, neurons were grown on poly-Lysine coated glass coverslips 
as previously described (71) and fixed with 4% formaldehyde (Ted Pella, Inc.) in PBS for 10 
minutes at room temperature. Fixed neurons were then permeabilized with 0.1 % Triton X-100 
in PBS for 5 minutes. Unspecific binding was blocked with 3% BSA, 3% FBS in PBS for one hour 
at room temperature. Fixed neurons were then probed with antibodies for 3-NT (1:500, Sigma) 
and an antibody specific for MAP 2 protein (1:200, Invitrogen) (RT, 2h), a neuronal marker 
followed by conjugated fluorescent secondary antibodies AlexaFluor594 or AlexaFluor488 
(respectively) at dilutions of 1:500 (RT, 2h). Chromatin was stained by incubating fixed samples 
with Hoechst 33342 (1 μg/ml) in PBS at RT for 5 min. To visualize 3-NT using AlexaFluor594, the 
excitation filter was S555/28× (Chroma) and the emission filter was S617/73m (Chroma), to 
visualize neurons using AlexaFluor488, the excitation filter was S490/20× and the emission filter 
was S528/38m (Chroma) and to visualize Hoechst 33342 the excitation filter was S403/12× and 
emission filter S475/50m. Immuno-staining conditions for 3-NT were first optimized along with 
a blocking control, using 10 mM nitro-tyrosine, to confirm specificity of 3-NT signal. 
Fluorescence microscopy was performed as previously described (112). Quantification of 
fluorescence from 3-NT was as follows. Exposure time, brightness and contrast of randomly 
selected cortical neurons were held constant for all images within same experiment. Using 
MetaMorph 7.5, a region of interest was selected around each neuron using the MAP 2 label as 
a guide. This region was transferred to the 3-NT image channel. The fluorescence intensity for 
each neuron was measured using Show Region Statistics function. Area and 
intensity/fluorescence data was logged for each neuron. Twenty five to fifty neurons from each 
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treatment were evaluated for a total of over 100 neurons per experiment. Three areas were 
selected randomly within each image and the average of their fluorescence intensity was 
considered as background. The background was subtracted within each image. 3-nitrotyrosine 
immuno-fluorescence quantification is expressed as fluorescence per µm2.  
APF Live Cell Imaging 
Neurons were cultured on poly-Lysine coated MatTek dishes. To visualize peroxynitrite 
in neurons, cell permeable APF (2.4 µM) (Molecular Probe) was loaded in Neurobasal medium 
(phenol red free) containing 0.2 % pluronic acid, 1.8 mM CaCl2, 0.8 mM MgCl2, Hoechst 33342 
(1 μg/ml) for 30 minutes at 37C in a humidified 5% CO2. Dye was then removed and replaced 
with conditioned phenol red-free Neurobasal medium. The APF fluorescent signals were 
measured in response to SNOC (100 µM) at two hours. Z-stacks were acquired keeping the 
exposure time, brightness and contrast constant using excitation S490/20× and emission 
S528/38m filters (Chroma). Using MetaMorph 7.5 software (Molecular Devices), equal 
backgrounds were subtracted from each z-stack image (as determined from each experiments 
control images) then z-stack series were summed. Cell soma and processes were selected, as 
previously described, using region of interest drawn around cell. This region was transferred to 
the APF image channel. The fluorescence intensity for each neuron was measured using Show 
Region Statistics function. Intensity/fluorescence data was logged for each neuron and data 
exported to Excel for further analysis.  
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Nanoceria Preparation  
Nanoceria were synthesized by a wet chemical process as previously described (81). In 
brief, to prepare nanoceria with a high ratio of Ce3+/ Ce4+, Ce (NO3)3 ∙ 6H2O (5 mM) was 
dissolved in dH2O and the nitrate precursor was stirred for 15 min then H2O2 (2% v/v) was 
rapidly added while stirring at 300 rpm. The solution was continuously stirred for 1 h to obtain a 
stable dispersion of cerium oxide nanoparticles.  Samples were stored at room temperature. All 
preparations were sonicated to ensure single nanoparticles (Branson, Danbury, CT) for 45-60 
min prior use. For cell experiments, nanoceria were diluted in sterile water. 
Transmission Electron Microscopy (TEM) 
Neurons were cultured on poly-Lysine coated 35 mm MatTek glass bottom dishes and 
fixed with 2 % paraformaldehyde, 0.15 M sodium cacodylate, pH 7.4,  2.5 % glutaraldehyde for 
five minutes at room temperature and followed by an additional 30 minutes on ice. The fixed 
cells were then washed three times with ice-cold 0.15 M sodium cacodylate and 3 μM calcium 
chloride for three minutes on ice and followed by postfixation in 1 % osmium tetroxide, 0.8 % 
potassium ferrocyanide, 3 μM calcium chloride in 0.15 M sodium cacodylate for 60 minutes on 
ice. After washing cells three times with ice-cold ddH2O for three minutes each, the cultures 
were stained in 2 % uranyl acetate for 30 minutes on ice. Samples were dehydrated with ice-
cold 20, 50, 70, 90 % ethanol and then with 100 % ethanol at room temperature. The samples 
were first infiltrated in 50 % ethanol/50 % Durcupan ACM (Fluka/Sigma) for 1 hour at room 
temperature and under agitation, followed by three changes of 100 % Durcupan for three 
hours. The resin was polymerized at 80 ⁰C for three to four days under vacuum. Sectioning was 
41 
 
performed using AO/Reichert Ultramicrotome. Ultrathin (80 nm) sections were post-stained 
with uranyl acetate (five minutes) and lead salts (two minutes) prior to imaging using a JEOL 
1200FX transmission EM operated at 80 kV. A subset of sections was imaged without poststain. 
Negatives were shot at a magnification of 20,000. The negatives were digitized at 1800 dpi 
using a Nikon CoolScan system, giving an image size of 4033 × 6010 pixels and a pixel resolution 
of 0.71 nm. 
The nanoparticle morphology was characterized using high-resolution transmission 
electron microscopy (HRTEM). The nanoceria preparation was deposited on the carbon-coated 
copper grid (SPI supplies) for HRTEM analysis. The TEM grid was dipped into the nanoceria 
preparation by the dip coating technique.  HRTEM micrographs were obtained using FEI Tecnai 
F30 operated at 300 keV.  
Statistics 
Results were collected from at least three or more independent experiments and are 
expressed as mean ± standard deviation (s.d.). Statistical analysis of two populations was 
compared using two-tailed non-paired Student’s t test. 
Results  
Nanoceria Accumulate at Mitochondria in Neurons 
First, we determined the properties of our CNP1 preparation to confirm their Ce3+ 
oxidation state, fluorite structure and cerium spectrum (CD&D under review). To assure sterile 
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conditions during growth of cortical neuronal cultures, CNP1 were filtered prior to use. To 
assure that CNP1 would not be prevented from going through 2 µm filter, possibly due to 
electrostatic attractions, the UV-visible spectrum before and after filtering were analyzed 
(Figure 7) and were determined to be identical.  Previous reports suggest that CNP1 are readily 
internalized by cells, owing to their small size of ~ 5 nm (98, 131). We first checked for CNP1 
(100 nM) uptake in our cultured cortical neurons using inductively coupled plasma mass 
spectroscopy (ICP-MS) over a time-course of twenty four hours (Figure 8). Cerium was easily 
detected in neurons after 1 h and reached steady state concentrations after 2 h. 
CNP1 are internalized by cells owing to their small size (98, 131). However, their 
subcellular localization in neurons remains unclear. Therefore, we tracked the presence of 
CNP1 in primary rat cortical neurons using transmission electron microscopy (TEM). While 
untreated neurons exhibited no detectable signal (Figure 9A), we obtained clear evidence of 
electron dense particles in neurons cultured with CNP1 for three, twelve or twenty four hours. 
Specifically, CNP1 were present at two primary locations: the mitochondrial outer membrane 
and inner leaflet of the plasma membrane (Figure 9B,C). To verify that the electron dense 
granules indeed reflected CNP1, we repeated the EM preparation using samples void of post-
staining. Using this modification we still detected electron dense particles, suggesting that they 
are not an artifact and indeed represent the nanoparticles (Figure 9D). The size of our CNP1 
particles were ~ 3 to 8 nm (Figure 9E), in agreement with previous reports (101). However, the 
electron dense particles within neurons were larger, measuring 20.6 nm (± 2.9 nm s.d.). This 
increased size is expected since oxide nanoparticles rapidly agglomerate in cells, owing to their 
surface interactions with biological material. Further quantification of the association of CNP1 
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particles with mitochondria (Figure 9F) or the plasma membrane (Figure 9G) confirmed that 
their location aligns with sites of increased ROS/RNS production in neurons. Analyses of the 
nuclei from non-post-stained images revealed very few CNP1 (data not shown). In summary, 
the data suggests that CNP1 become internalized by neurons and accumulate at the 
mitochondrial outer membrane and inner leaflet of the plasma membrane.  
CNP1 Protect Against Nitrosative Stress 
Next, we tested whether CNP1 would lower nitrosative stress in neurons exposed to the 
·NO donor S-nitrosocysteine (SNOC). The levels of nitrosative stress were measured by live cell 
labeling with the RNS/ROS-sensitive fluorescent probe 3'-(p-aminophenyl) fluorescein (APF). 
Fluorescence microscopy indicated that neurons exposed to either aged SNOC, - which released 
all ·NO owing to its poor stability-, or CNP1 alone displayed low baseline APF fluorescence 
(Figure 10A(a) and 10A(b)). By contrast, neurons exposed to fresh SNOC showed a clear 
increase in fluorescence, reflecting APF oxidation (Figure 10A(c)). Importantly, neurons 
pretreatment with CNP1 for 3 hours abolished the SNOC-induced increase in APF fluorescence, 
suggesting that CNP1 were able to neutralize ROS/RNS in neurons (Figure 10A(c) and 10A(d)). 
Notably, the APF fluorescent signal in SNOC-exposed neurons revealed a mottled cytoplasmic 
pattern (Figure 10A(c)). It is possible the APF marks mitochondria, exhibiting increased 
RNS/ROS levels. Further quantitative analyses confirmed a significant decrease of APF oxidation 
in SNOC plus CNP1 treated neurons compared to SNOC alone treated neurons (Figure 10B).  
Finally, CNP1 significantly protected neurons from SNOC-induced cell death (Figure 10C).  
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CNP1 Reduce Peroxynitrite-induced Protein Tyrosine Nitration 
The modification of tyrosine residues can elicit changes in protein structure and 
function. Protein tyrosine nitration is a frequently used diagnostic marker for nitrosative stress 
and neurodegeneration (132). We tested whether CNP1 would reduce the burden of SNOC-
induced protein tyrosine nitration using immunocytochemistry of fixed neuronal cultures and 
pan antibodies for 3-nitrotyrosine. Using fluorescence microscopy we observed that control 
neurons, - treated with either aged SNOC or CNP1 alone-, exhibited low background 3-
nitrotyrosine immunofluorescence (Figure 11A(a) and 11A(b)). By contrast, SNOC-exposed 
neurons showed a robust increase in fluorescence, reflecting increased protein tyrosine 
nitration (Figure 11A(c)). Remarkably, CNP1 prevented SNOC-induced tyrosine nitration, 
evidenced by the reduced fluorescent intensity (Figure 11A(d)).  Quantitative analyses 
confirmed a significant reduction in the relative 3-nitrotyrosine signal in neurons that were 
pretreated with CNP1 (Figure 11B). Finally, we analyzed the relative 3-nitrotyrosine 
immunoreactivity of neuronal cell lysates with western blotting. Again, CNP1 reduced the 
SNOC-induced total protein tyrosine nitration, confirming our in situ data using intact neurons 
(Figure 11C). These findings suggest that CNP1 might be a useful tool to attenuate the harmful 
effects of protein nitration.  
CNP1 Protect Against Aϐ induced Mitochondrial Fragmentation 
Nitrosative stress plays an important role in A-mediated neurotoxicity (74, 84). A  or 
nitrosative stress evoke persistent mitochondrial fragmentation, an event that causes 
bioenergetic failure, impaired Ca2+  homeostasis, synaptic injury, axonal transport defects, and 
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neuronal cell death (71, 133).  To test whether CNP1 would prevent the A-induced 
mitochondrial fragmentation, we visualized the mitochondrial morphology by fluorescence 
microscopy in neurons expressing DsRed2-Mito, a red fluorescent protein targeted to the 
mitochondrial matrix. Control neurons, - either left untreated or treated with CNP1 alone (3 h 
pretreatment)-, demonstrated an elongated mitochondrial morphology, typical of healthy 
neurons (Figure 12A(a) and 12A(b)). By contrast, oligomeric A 25-35 peptide, but not the 
reverse A 35-25 control peptide (Figure 12A(g)), induced dramatic mitochondrial 
fragmentation evidenced by the appearance of mitochondria with mostly round morphology 
(Figure 12A(c)). Remarkably, CNP1 prevented the A25-35-induced mitochondrial 
fragmentation, similar to N-acetyl-L-cysteine (NAC), a known ·NO/ONOO- neutralizing 
antioxidant supplement (Figure 12A(d) and 12A(f)). Further quantitative analysis demonstrated 
that CNP1 significantly reduced the A-induced mitochondrial fragmentation in neurons (Figure 
12B). These results suggest that CNP1 not only accumulate at mitochondria, but can also 
preserve their morphology and function in response to neurotoxic insults such as A 
CNP1 Reduce DRP1 Phosphorylation at S616 
There is increasing evidence that mitochondrial fragmentation, owing to excessive 
DRP1-dependent  mitochondrial fission, plays a central role in many neurodegenerative 
disorders including AD (73, 111, 118, 134). Cdk1/cyclinB1-mediated phosphorylation of DRP1 at 
S616 causes its recruitment from the cytoplasm to mitochondria to initiate organelle division in 
mitotic cells (119). However, all Cdk’s are inactivated in postmitotic neurons with the exception 
of Cdk5. Over-activation of NMDA receptors by A  triggers excessive nitrosative stress and 
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cytoplasmic Ca2+  levels. (121) possibly leading to increased ·NO production. SNOC triggers DRP1 
S616 phosphorylation and mitochondrial fragmentation (71, 117). Notably, p-DRP1 S616 is 
increased in AD patient brains (117, 121, 135). Because CNP1 prevented A-induced 
mitochondrial fragmentation (Figure 12), we questioned whether they might inhibit DRP1 S616 
phosphorylation, providing an explanation for the preservation of mitochondrial morphology by 
CNP1. Neurons treated with either aged SNOC or CNP1 alone exhibited only low baseline DRP1 
S616 phosphorylation (Figure 13A). By contrast, neurons treated with fresh SNOC exhibited 
high p-DRP1 S616 levels (Figure 13A). Remarkably, CNP1 significantly reduced the SNOC-
induced increase in DRP1 S616 phosphorylation (Figure 13A). Similarly, CNP1 or NAC abolished 
the Aβ 25-35-induced DRP1 S616 phosphorylation (Figure 13B). These results suggest that CNP1 
reduce nitrosative stress or A-induced mitochondrial fragmentation perhaps by preventing 
DRP1 S616 hyperphosphorylation.  
CNP1 Protect Against Aϐ -induced Neuronal Cell Death 
Cell death by A or NMDA occurs, at least in part, through endogenous RNS/ROS (71).  
Neuronal death by the complex II inhibitor 3-nitropropionic acid (3-NP) triggers secondary 
excitotoxicity and RNS/ROS (128). A 25-35, but not the reverse peptide, elicited neuronal cell 
death, which was reduced in the presence of either CNP1 or NAC (Figure 14A). Similarly, 
neuronal cell death by excess NMDA or glutamate was reduced by CNP1 (Figure 14B and 14C). 
Finally, similar neuroprotective effects were observed against respiratory complex II inhibition 
by 3-NP (Figure 14D). Thus, CNP1 provide neuroprotection against a variety of insults that 
generate endogenous ROS/RNS.  
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Discussion 
Nitrosative stress and mitochondrial dysfunction are early features of AD, therefore 
targeting these events might offer therapeutic benefits. Several antioxidants including β-
carotene, vitamins C and E, NAC (12), coenzyme Q10  (13) and tetra-hydrocurcumin provided 
protective effects in cellular and animal models of AD (14). However, their efficacy in human 
trials provided at best only modest effects (12, 15, 16). Among the problems are their poor 
stability and repetitive dosing, underscoring the need for alternative strategies.  
To overcome this problem we integrated nanotechnology with neuroscience. Here, we 
tested the effects of CNP1, which are inorganic auto-catalysts with antioxidant properties. Thus, 
a single dose might suffice, unlike conventional antioxidants. Mitochondrial dynamics are 
sensitive to many stimuli including ROS/RNS (111). Mitochondrial fission is activated by DRP1 
when mitochondrial ROS levels are increased (136).  We provide evidence that CNP1 are able to 
reduce ROS/RNS, which in turn lowers DRP1 S616 hyperphosphorylation, mitochondrial 
fragmentation and neuronal cell death by A, NMDA receptor overactivation, and 
mitochondrial respiratory chain inhibitors. 
There are reports which claim that  CNP1 are toxic (66). In considering CNP1 as potential 
therapeutic agents it is important to pay attention to their synthesis method, concentration, 
and surface chemistry. The preparation of water-based CNP1 in our study has been shown to 
exhibit SOD mimetic activity (55, 126) whereas other synthesis methods result in CNP1 without 
comparable antioxidant properties (66). Thus these factors might account for the seemingly 
conflicting reports. Mild nitrosative/oxidative stress provides cell protective effects and plays an 
important physiological role. A concern would be that antioxidants might eradicate the 
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cytoprotective effects of mild stress.  Our data shows that CNP1 are not toxic to neurons, 
suggesting that they do not lower physiological levels of nitrosative/oxidative stress.  
We reduced in situ ROS/RNS as visualized by decreasing APF oxidation (Figure 10) as 
well as 3-nitrotyrosine nitration in SNOC stressed neurons (Figure 11A,C) and protection from 
cell death by Aβ 25-35 exposure (Figure 13A) using CNP1. Increased levels of nitrated proteins 
have been reported in AD brains as well as cerebrospinal fluid in patients with AD (37). 
Numerous proteins in AD have been shown nitrated by peroxynitrite (33). Peroxisome 
proliferator-activated receptor gamma (PPARγ) expression protects neurons from Aβ- mediated 
toxicity (38) however its nitration prevents its translocation to the nucleus, thereby preventing 
mitochondrial biogenesis (39). A disrupted energy metabolism and ROS/RNS redox balance can 
activate redox-sensitive transcription factors including activator protein-1 (AP-1). Increased 
iNOS expression by AP-1 is implicated in AD (137).  
Nitrosative stress can activate kinases (109, 110). Specifically peroxynitrite can activate 
p38 MAP kinase and Cdk5 (108). Neurotoxic signals including Aβ and excess glutamate or 
NMDA causes an impaired Ca2+ homeostasis, which can activate downstream mediators 
including NOS and calpain (128). ROS/RNS can directly activate Cdk5. Aberrant Cdk5 activation 
in neurodegeneration can occur by two mechanisms. First, nitrosative stress can directly 
activate Cdk5 by increasing its phosphorylation. Second, Ca2+-dependent calpain cleavage of the 
Cdk5 activator p35 to p25 increases its stability. Consequently, Cdk5/p25 is constitutively 
activated. (111, 115, 123, 138). The blockage of mitochondrial fragmentation by CNP1 in 
response to Aβ was associated with a reduction in DRP1 S616 hyperphosphorylation (Figure 
13B).  Although it is unlikely that nitrosative stress mediates mitochondrial fragmentation and 
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neuronal cell death only by phosphorylating a single protein target, such as DRP1, our data 
describes one possible mode of action how CNP1 may specifically attenuate the downstream 
effects of RNS/ROS.  
Most therapeutic treatments of AD have targeted reducing or clearance of Aβ with 
disappointing results however, therapeutic strategies aimed at reducing mitochondrial damage, 
especially through mitochondrial antioxidants (13) show promise. Considering CNP1’s proximity 
to mitochondria (Figure 1F) they may be uniquely situated to protect neurons in AD from 
nitrosative stress and mitochondrial dysfunction by lowering DRP1 S616 phosphorylation and 
thereby maintaining bioenergetic function and neuronal viability.  
CeO2 NPs have been shown to decrease RNS/ROS-induced damage by many stress 
stimuli and in several cellular and animal models (101).  No toxicity or adverse effects to CeO2 
NPs in the eyes of rats was found, where it prevents vision loss  due to increased ROS from 
excess light exposure (139). CeO2 NPs also mitigate ischemic brain injury where CeO2 NPs 
markedly decreased the levels of 3-nitrotyrosine (3-NT) (98)  In addition, CeO2 NPs accumulated 
on mitochondria, consistent with our results (Figure 9F). The small size of CNP1 allowed 
passage into our neurons (Figure 9B), but delivery routes into all cell types and tissues must still 
be tested. These are not trivial issues, yet considering our results that CNP1 protected cortical 
neurons from multiple nitrosative-associated stressors, they represent a potential exciting 
alternative strategy compared to traditional antioxidants.  Our study represents an important 
step forward to test the potential neuroprotective effects of CeO2 NPs in in vivo animal models 
of AD. 
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Figures 
 
Figure 7: UV-visible spectroscopy analysis of sterile filtered CNP1 used in tissue culture 
experiments confirming 3+ oxidation state of CNP1 
Absorbance between 230-260 nm is indicative of Ce 3
+
 oxidation state. 
 
Figure 8: Time-course uptake of CNP1 measured by ICP-MS. 
Cortical neurons were incubated with 100 nM CNP1 for times indicated and the concentration 
of cerium inside neurons were measured by ICP-MS. 
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Figure 9: CNP1 accumulate at the mitochondrial outer mitochondria and the inner leaflet of 
the plasma membrane in cultured cortical neurons. 
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(A) Electron microscopy of an untreated control neuron. Scale bar, 1μm.  (B) Electron 
microscopy of a neuron treated with CeO2 nanoparticles (100 nM) for 3 hours. Round electron 
dense particles, indicative of CNP1 particles, concentrate around mitochondria (*) and the 
plasma membrane (black arrowhead), but not along the nucleus (N). (C) Electron microscopy of 
a neuron treated with CeO2 nanoparticles (100 nM) for 12 hours. Mitochondrion (*) showing 
clusters of CNP1 particles accumulating at the mitochondrial outer membrane. (D) Electron 
microscopy of a neuron treated with CeO2 nanoparticles (100 nM) for 3 hours for which the 
poststaining step was omitted. The mitochondrion is depicted by the (*) symbol. (E) High 
resolution transmission electron microscopy of a CNP1 particle. Parallel lines indicate the inter-
planar spacing of the atomic arrangement “d” showing the ceria lattice distance of 0.312 nm (as 
measured by the diffraction pattern, (Supplemental Figure 1C) and a Miller index of (111). Scale 
bar, 5 nm. (F) Bar graph of number of CNP1 particles in proximity to the mitochondrial outer 
membrane (G) or the inner leaflet of the plasma membrane. The closest distance between a 
CNP1 particle and a mitochondrion or the plasma membrane was measured with ImageJ and 
then binned in 100 nm increments.  
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Figure 10: CNP1 scavenge reactive nitrogen species and rescue cortical neurons from SNOC-
induced cell death. 
(A) Fluorescence images of APF (green) and Hoechst 33342 (blue) double staining of neurons 
treated with (a) aged SNOC (100 μM), (b) CNP1 (100 nM), (c) fresh SNOC (100 μM), or both (d) 
CNP1 (100 nM) and SNOC (100 μM) for two hours. Scale bar, 10 μm. (B) APF fluorescence of 
neurons treated with aged SNOC, CNP1, fresh SNOC, or CNP1 and SNOC at two hours. (C) Cell 
death of neurons at three hours treated with aged SNOC, CNP1, or fresh SNOC alone or in 
combination of CNP1 plus fresh SNOC. Data represent means ± standard deviation (s.d.). 
Results are representative of three or more independent experiments. Statistics: Student’s t 
test. 
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Figure 11: CNP1 reduce protein tyrosine nitration in SNOC exposed cortical neurons. 
(A) Fluorescence micrographs of 3-nitrotyrosine (red) immunostaining and Hoechst 33342 
(blue) staining of neurons treated with (a) aged SNOC (100 μM), (b) CNP1 (100 nM) (3 h 
pretreatment), (c) fresh SNOC (100 μM) alone, or (d) in combination with CNP1 and SNOC for 
three hours. Scale bar, 10 μm. (B) 3-Nitrotyrosine fluorescence of neurons treated with aged 
SNOC, CNP1, fresh SNOC, or CNP1 and SNOC for three hours. Data are means ± s.d. (C) Western 
blot of 3-nitrotyrosine protein modification in neurons treated with aged SNOC, CNP1, fresh 
SNOC, or CNP1 and SNOC for three hours. Fold densitometries represent the relative ratios of 
3-nitrotyrosine in whole neuronal lysates normalized to control lysates. Data are representative 
of three or more independent experiments. Statistics: Student’s t test. 
55 kD
43 kD
17 kD
11 kD
130 kD
3
-N
it
ro
 t
yr
o
s
in
e
F
lu
o
re
s
c
e
n
c
e
 (
a
.u
.)
p= 0.0032
100
80
60
40
20
0
B C
A
WB: Actin
1     1.2   2.2   1.05      Fold (A.U.)
W
B
: 
3
-N
it
ro
 t
yr
o
s
in
e
3-Nitrotyrosine
Hoechst 33342
(a) Aged SNOC
(c) SNOC (d) CNP1  + SNOC
(b) CNP1
1- Aged SNOC
2- CNP1 
3- SNOC
4- CNP1 + SNOC
Sample 1          2         3          4  
55 
 
 
(a) Untreated
(e) NAC
(b) CNP1
(f) NAC + Aβ 25-35
(d) CNP1  + Aβ 25-35
(g) Aβ 35-25
A
(c) Aβ 25-35
 3  3
 3
 3
 3
 3
 3
F
ra
g
. 
M
it
o
c
h
o
n
d
ri
a
(%
 N
e
u
ro
n
s
)
B
50
40
30
20
10
0
p
=
0
.0
0
1
p
=
0
.0
0
5
1- Untreated
2- CNP1 
3- Aβ 25-35
4- CNP1 + Aβ 25-35
5- NAC
6- NAC + Aβ 25-35
7- Aβ 35-25
Sample     1      2      3      4     5      6     7  
56 
 
Figure 12:   P1 pr v nt Aβ-induced mitochondrial fragmentation. 
(A) Fluorescence micrographs (scale bar, 50 μm) and 3 x zoom of boxed regions of 
mitochondrial morphology in neurons expressing DsRed2-Mito and (a) left untreated or treated 
with (b) CNP1 (100 nM) (3 h pretreatment), (c) or Aβ 25-35 (10 μM), (d) CNP1 and Aβ 25-35, (e) 
NAC (50 μM) (3 h pretreatment), (f) NAC and Aβ 25-35, (g) or the reverse Aβ 35-25 (10 μM) 
peptide for six hours. (B) Mitochondrial fragmentation in neurons expressing DsRed2-Mito and 
after treatment for six hours with CNP1, NAC, or Aβ 25-35 alone or in combination with either 
CNP1 and Aβ 25-35 or NAC and Aβ 25-35. Data are representative of three or more 
independent experiments. Results are means ± s.d. Statistics: Student’s t test. 
 
Figure 13: CNP1 abolish DRP1 phosphorylation at S616 in response to RNS. 
(A) Western blots of p-DRP1 S616, total DRP1, and actin protein levels from neurons exposed 
for three hours to aged SNOC (100 μM), CNP1 (100 nM) (3 h pretreatment), or fresh SNOC (100 
μM) alone or in combination. The bar graph represents the relative ratios of p-Drp1 S616 to 
total DRP1 protein and normalized to actin. (B) Western blots of p-DRP1 S616, total DRP1, and 
actin protein levels from neurons exposed to CNP1 (100 nM), preaggregated 10 μM Aβ 25-35 
for 6 h, or in combination as well as NAC (50 μM) (3 h pretreatment) with Aβ 25-35. The bar 
graph illustrates the relative ratios of p-DRP1 S616 to total DRP1 protein, normalized to actin. 
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Figure 14:   P1 d lay n uronal c ll d ath induc d by Aβ,  MDA, glutamat , or  -NP. 
(A) Cell death of neurons treated with either CNP1 (100 nM) (3 h pretreatment), NAC (50 μM) 
(3 h pretreatment), or Aβ 25-35 (10 μM) alone, or both CNP1 and Aβ 25-35, or NAC and Aβ 25-
35 at six hours. Untreated cells or reverse Aβ 35-25 (10 μM) peptide treatment served as 
negative controls. (B) Excitotoxic cell death of neurons exposed to either NMDA (150 μM), or 
CNP1 (100 nM) (3 h pretreatment), or in combination of both for 12 hours. (C) Excitotoxic cell 
death of neurons exposed to either glutamate (150 μM), or CNP1 (100 nM) (3 h pretreatment), 
or in combination of both for six hours. (D) Cell death of neurons exposed to mitochondrial 
respiratory complex II inhibitor 3-NP (10 mM), or CNP1 (100 nM) (3 h pretreatment), or in 
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combination of both for eight hours. Results are representative of three or more independent 
experiments. Data are means ± s.d. Statistics: Student’s t test. 
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CHAPTER 4: ATPASE/PHOSPHATASE ACTIVITY UNDERLIES THE TOXICITY OF 
HEXAMETHYLENETETRAMINE-BASED CERIUM OXIDE NANOPARTICLES 
Introduction 
Cerium is a rare earth metal that belongs to the Lanthanides series of the periodic table. 
It has the unique property in that oxygen vacancies are created in their metal oxide 
nanoparticle form (140). Cerium oxide NPs retain their fluorite lattice structure even with the 
loss of oxygen, yielding CeO2-x, and vacancies are the likely sites for potent reduction-oxidation 
(redox) reactions (88). It is this property that first made it useful for industrial applications 
including the removal of carbon monoxide (CO), hydrocarbons and nitric oxide species (NOx) 
from exhaust gas (87). In addition, the ability to shift between Ce3+ and Ce4+ states plays an 
important role in CeO2 NPs  capacity to interact with a variety of  reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) species (55, 67, 68, 126). It is this ability to scavenge 
ROS/RNS species that has led to CeO2 NPs testing in biological systems to reduce potentially 
harmful ROS/RNS in disease and aging as use as potential therapeutics.  
Nanoparticles in general exhibit novel surface properties that can affect their chemistry 
and their interaction with biological systems. For CeO2 NPs to be a realistic therapeutic, they 
must be understood completely before human testing can be started and carefully 
characterized in order to insure safety. Part of that understanding must include the synthesis 
process in which the CeO2 NPs have been created. The processing and material preparation of 
CeO2 NPs are wide and varied, this includes creating NPs with the core CeO2 material as well as 
surface functionalization and/or modifications (66). Even when synthesizing ‘bare’ CeO2 NPs, 
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there are numerous synthesis methods that have been employed (141-143). Over the past 
decades, better synthesis methods for CeO2 NPs use have been extensively tested for industrial 
(144) and biological uses. For use in biological studies, three major synthesis themes have been 
described, direct high-temperature exposure processes, heated in solvent synthesis and room 
temperature synthesis (66) resulting in various biological responses.  The aim of these new 
synthesis methods was to create NPs with high oxygen storage capacity, uniform size, specific 
size, and catalytic activity. The use of heated hexamethylenetetramine (HMT) as a solvent 
results in finer CeO2 NPs (145) and is routinely employed in the synthesis of CeO2 NPs (65, 146, 
147). The catalytic properties of these HMT-based CeO2 NPs have not yet been determined in 
biological systems. There are many studies using room temperature/water-based synthesis of 
CeO2 NPs in which various catalytic activities have been described (55, 67, 68, 126). The 
rationale for this synthesis method is that they seem to be less toxic (60, 148, 149) and the 
ability to control the Ce3+/Ce4+ ratio (81). Indeed, for CeO2 NPs to be a potential therapy for the 
reduction ROS/RNS in disease, the mechanism of action for CeO2 NPs, respective of synthesis 
procedure, must be well defined.  
The study of the chemical and biological properties of CeO2 NPs has expanded recently. 
There are numerous studies that point to CeO2 NPs as a potential new treatment for a wide 
variety diseases (58, 98, 99, 150). Although most of the focus has been on the ability of these 
materials to reduce reactive oxygen and nitrogen species in biological systems, there are 
reports that claim that CeO2 NPs are toxic. Unfortunately, the material synthesis of these 
studies varies significantly. Thus it must first be determined whether CeO2 NPs made by 
different methods are similar or different in their chemical properties. Then the next step is to 
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determine the pathways that CeO2 NPs might interfere or augment. Mechanisms for anti-
oxidant or pro-oxidant for CeO2 NPs are now just starting to be compared. However, the 
outcomes of CeO2 NPs exposure can vary as much as the synthesis methods and cell types 
tested (151-153). This underscores the need to fully understand the nanoparticles synthesis 
method, resulting catalytic behavior(s) and their influence(s) in biological settings. 
Phosphorylation and dephosphorylation play a significant role in a wide range of 
important regulatory mechanisms in mammals. Control of the addition or removal of 
phosphate (PO4
3-) groups is especially important energy maintenance, specifically adenosine 
triphosphate (ATP) which is a critical energy storage molecule. The hydrolysis of ATP to 
adenosine diphosphate (ADP) releases energy (H+) and inorganic phosphate which is then 
utilized in a wide range of cellular applications such as the movement of organelles 
(endosomes, lysosomes, mitochondria) along microtubules as well as muscle contractions, 
small molecule transport, or biosynthetic reactions driving anabolism. Unregulated hydrolysis 
of ATP to ADP will strain energy metabolism and have a negative impact on a cell’s ability to 
function normally. In this study we compared CeO2 NPs synthesized by two different methods 
(water-based and HMT-based) to begin to understand the enigma of how CeO2 NPs can be 
reported to be both toxic and non-toxic when exposed to a variety of organisms and cells in 
culture at similar concentrations. Based on our results, we hypothesize that the toxicity 
reported by many investigators may be due to phosphatase activity of CeO2 NPS that proceeds 
through a poorly understood catalytic mechanism at the surface of the nanoparticle.  
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Materials and Methods 
Preparation of Different Cerium Oxide Nanoparticles 
In this study several cerium oxide nanoparticles were prepared with varying surface 
oxidation state, surface modification, and morphology. Cerium nitrate hexahydrate (99.999% 
pure from Sigma Aldrich, St. Louis, MO) were used as a precursor for all of the preparations. 
Cerium oxide nanoparticles with a higher Ce3+/Ce4+ ratio (CNP1) or  with lower Ce3+/Ce4+ ratio 
(CNP 2) were prepared using wet chemical method as described previously (154). Surface 
modified cerium oxide nanoparticles were prepared using hexamethylenetetramine (HMT) 
(155). Briefly, equal volume of 37.5 mM of cerium nitrate solution and 0.5 M HMT were mixed 
together and stirred for 24 h at room temperature. Cerium oxide nanoparticles prepared using 
HMT were washed with either ethanol and acetone or dH2O for three times and finally 
resuspended in dH2O. It is important to mention that after washing with ethanol and acetone, 
CNP-HMT-1 were washed with dH2O (three times) to remove any trace amount of solvent 
(ethanol or acetone) before resuspending in dH2O.  Cerium oxide nanoparticles washed with 
ethanol and acetone to remove the maximum amount HMT were designated as CNP-HMT1. 
CNPs washed with only dH2O were designated as HMT-CNP2. Different morphology of CNP-
HMT3 were prepared by preheating the both the solutions (37.5 mM cerium nitrate precursor 
and 0.5 M HMT) at 60° C and then equal volume of the solutions were mixed and stirred for 4 h. 
CNP formed were then washed with ethanol and acetone for three times and finally with dH2O 
to remove the solvent before resuspending in dH2O.  
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Physico-Chemical Properties of Cerium Oxide Nanoparticles (CeO
2
) 
High resolution transmission electron microscopy (HRTEM) was used to analyzed size 
and morphology of the nanoparticles. Hydrodynamic radius and surface charge of the 
nanoparticles were estimated using Zetasizer (Nano-ZS from Malvern Instruments, Houston, 
TX). X-Ray photoelectron spectroscopy (5400 PHI ESCA) used to determine the surface 
oxidation state of the nanoparticles. Mg-Ka X-radiation (1253.6 eV) and 350 W power was used 
during the data collection as previously described (154). Fourier transform infrared (FTIR) 
spectra were collected to confirm the presence of HMT molecule on the nanoparticle surface 
using PerkinElmer Spectrum IR Spectrophotometer (Waltham, MA). The amount of HMT that 
remains on the surface of the nanoparticles was determined with differential scanning 
calorimetry and thermogravimetric analysis (DSC-TGA) using a TA Instruments SDT-Q600 (New 
Castle, DE), with open alumina pans under 100 mL/min air flow. Particle size analysis was also 
carried out by measuring the specific surface area (m2/g) using the Brunauer, Emmett, and 
Teller (BET) method with a Quantachrome Nova 4200e surface area analyzer (Boynton Beach, 
FL). 
Drosophila melanogaster Exposure to Water-based or HMT-based Cerium Oxide Nanoparticles. 
Male and female wild-type D. melanogaster (Oregon R) were maintained under optimal 
conditions in a standard corn meal medium at a temperature of 25°C. Larval exposure to 
nanoparticles began at the larvae stage and continued through eclosion. Parental crosses were 
set up in cages with 150 females and 30-40 males on grape plates seeded with live yeast. After 
21 hours, each grape plate was changed and hatched larvae removed. Groups of 50 larvae from 
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grape plates were isolated using a mounting needle under a dissecting microscope and placed 
in vials containing 6 ml Jazzmix (Fisher Scientific, Pittsburg, PA) food medium containing 86 
μg/mL of nanoparticles, CNP1 or HMT-CNP1. Control larvae were cultured in parallel in food 
vials containing only H2O or 500 μM HMT. All vials were kept at 25°C and checked daily for 
pupariation and eclosion.  
Cultivation of HUVECs 
Human Umbilical Vein Endothelial Cells (HUVECs) (Lonza Walkerville, Inc., Walkersville, MD) 
were maintained at 37oC in a humidified atmosphere containing 5% CO2 in endothelial basal 
medium (EBM) (Lonza Walkerville, Inc., Walkersville, MD) supplemented with 2 % fetal bovine 
serum (FBS). Only cells from passages 3-6 were utilized in all experiments. 
Cell Viability MTT Assay 
HUVECs were cultured in 96-well plates and exposed to CeO2 NPs for 48 h. Thiazoyl blue 
tetrazolium bromide (MTT) (Amresco, Solon, OH) (1.2 mM) was added and cells were 
subsequently incubated for 4 h at 37 °C in 5% CO2 atmosphere. To solubilize the dye, 100 μL of 
cell lysis solution (10% SDS, 5 mM HCl) was added to each well and the plate was incubated for 
an additional 4 h at 37 °C. Absorbance of the soluble dye was recorded at 570 nm using a 
Spectra Max 190 spectrophotometer (Molecular Devices, Sunnyvale, CA). Cell viability was 
determined by dividing the absorbance of treated samples to untreated controls and reported 
as a percentage of control cells. Results were collected from at least three independent 
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experiments and are expressed as mean ± standard deviation (s.d.). Statistical analysis of two 
populations was compared using two-tailed non-paired Student’s t test. 
Analysis of Intracellular ATP Levels 
HUVECs were cultured in opaque-walled 96-well plates and treated with CeO2 NPs for 
48 h. Plates were equilibrated to room temperature and cells were lysed according 
manufacturer instructions. CellTiter-Glo® Reagent was added, plates were incubated for 10 min 
to stabilize the luminescent signal.  Luminescence was then recorded with a Varian Cary Eclipse 
fluorescence spectrophotometer (Palo Alto, CA) using 1 second integration time per well. 
Results were collected from at least three or more independent experiments and are expressed 
as mean ± standard deviation (s.d.). Statistical analysis of two populations was compared using 
two-tailed non-paired Student’s t test. 
ICP-MS Uptake of CeO2 NPs Studies 
HUVECs culture monolayers were incubated for 24 h with nanoparticles. Cells were 
washed two-times to remove extracellular nanoparticles and then collected by typsination and 
washed with PBS again to remove excess media and particles that could be adsorbed on the 
surface of the cells. Cells exposed to CNPs were analyzed for their cerium content using a 
Thermo Electron X-Series inductively coupled plasma mass spectrometer (ICP-MS, Thermo 
Scientific, Pittsburgh, PA) following APHA method 3125B to determine the amount of CNPs 
taken up by the cells. 
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Live Cell Imaging of HUVECs Exposed to CeO2 NPs 
HUVECs were cultured on Lab-Tek®II chambered coverglass (NUNC, Rochester, NY) slides 
in phenol red-free EBM (Lonza, Walkersville, MD) supplemented with  2 % FBS. Cells were 
exposed to various preparations of CeO2 NPs for 36 h. To visualize nuclei, Hoechst 33342 dye 
(Molecular Probes, Invitrogen, Eugene, OR) (1μg/mL) was added in medium for 10 min at 37°C 
in a humidified 5% CO2 incubator. Dye was removed and replaced with pre-warmed medium. 
Chamber slides with cultured HUVECs was placed under phase-contrast 40x air objective on a 
Nikon fluorescence microscope and images acquired at 37°C in a humidified 5% CO2 
atmosphere.   
Confocal Microscopy 
HUVECs were exposed to nanoparticles for 24 h and subsequently washed, trypsinized 
and seeded onto glass coverslips for 4 h (to allow for cell attachment). Cell were then fixed in 4 
% formaldehyde for 20 min at RT. Cells were washed two times in PBS and then labeled with 
wheat germ agglutinin (WGA), Alexa Fluor® 488 (Molecular Probes, Invitrogen, Eugene, OR) (5 
μg/mL) for identification of plasma membranes (green channel, excitation 405nm/emission 
498) and Hoechst 33342 for identification of nuclei (blue channel, excitation 405/emission 428). 
Cells were washed and mounted in anti-fade mounting media (Calbiochem, St. Louis, MO) and 
slides cured 24h at RT. Slides were stored at 4 °C until simultaneous confocal and bright field 
imaging by Leica TCS SP5 laser scanning confocal microscope with 40×/1.25 oil objective lens.  
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Phosphatase Mimetic Assay 
To measure the phosphatase activity of various CeO2 NPs, 1.2 mM of p-nitrophenyl 
phosphate (pNPP) (New England BioLabs Inc., Ipswich, MA) was incubated in a 96-well plate in 
the presence of various concentrations of CeO2 NPs (4.3, 8.6, 17, 34 μg/mL) in a total volume of 
200 μL H2O. The ability of CeO2 NPs to catalyze the hydrolysis of pNPP to p-nitrophenyl was 
measured by following the increasing absorbance (405 nm) every minute for 20 min using a 
Spectramax 190 UV-visible spectrophotometer (Molecular Devices, Sunnyvale, CA). 
ATPase Activity Assays 
The concentration of inorganic phosphate liberated by various preparations of CeO2 NPs 
was determined using a malachite green assay (R&D Systems, Minneapolis, MN). Nanoparticles 
(34 μg/mL) were added to ATP or GTP (Sigma Aldrich St. Louis, MO) (34 µg/mL) at various time 
points (0, 30 sec, 1 min, 2 min, 4 min, 6 min, 8 min ,10 min) at RT in 50 mM Tris buffer at pH 8.0. 
A phosphate standard curve was generated to enable quantitative determination of phosphate. 
The Malachite Green solutions were added to each well and the absorbance (620 nm) was 
determined using a Spectramax 190 UV-visible spectrophotometer (Molecular Devices, 
Sunnyvale, CA) after a 20 min incubation to stabilize the dye/PO4 complex.  
The concentration of inorganic phosphate liberated by various preparations of CeO2 NPs 
was also determined using EnzCheck Phosphate Assay (Invitrogen). The EnzCheck phosphate 
reaction is a fast, quantitative enzymatically linked assay in which in the presence of Pi, the 
substrate 2-amino-6-mercapto-7-methylpurine riboside (MESG) is converted enzymatically by 
purine nucleoside phosphorylase (PNP) to ribose 1-phosphate and 2-amino-6-mercapto-7-
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methyl purine. The conversion of MESG can be followed by the increase in absorbance at 360 
nm. Nanoparticles (34 μg/mL) were added to varying concentrations of ATP (Sigma Aldrich St. 
Louis, MO) and phosphate release followed every 30 sec for 30 min at 360 nm using a 
Spectramax 190 UV-visible spectrophotometer (Molecular Devices, Sunnyvale, CA) after an 
initial10 min incubation. A phosphate standard curve was generated to enable quantitative 
determination of phosphate in solution. Baseline changes due to hydrolysis of phosphate from 
ATP only controls was subtracted from each concentration to determine free phosphate 
liberated only by addition of CeO2 NPs. The kinetic parameters, Vmax  and Km were calculated by 
using SigmaPlot® 10 software (Systat Software, Inc., Point Richmond, CA). 
Analysis of DNA Stability in the Presence of Cerium Oxide Nanoparticles 
Preparations of nanoparticles were heated at 65o C for 15 minutes to denature possible 
endogenous (contaminating) DNase activity. The treated solutions were allowed to cool to 
room temperature. 1 µL (500 ng) of DNA ladder (Lambda HindIII digestion) was added 
nanoparticles in water and EDTA at a final concentration of 5 mM. Cerium oxide nanoparticle 
levels were varied in the presence of the same concentration of DNA. One set of incubations 
was placed at room temperature, and another was carried out at 37º C. DNA was analyzed by 
agarose gel electrophoresis using a 1% agarose gel in Tris-Acetate EDTA (TAE) buffer as 
previously described (156). DNA was analyzed by staining with ethidium bromide and viewed 
under trans illumination with UV light.  
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Results  
Cerium Oxide Nanoparticles (CeO2 NPs) Vary in Size, Shape, and Charge Depending Upon 
Synthesis Method 
Careful characterization of nanoparticle preparations used in a study is critical when 
addressing biological relevance. It is rare that the actual synthesis procedure is used as a 
variable. In this study we chose two types of synthesis procedures for making cerium oxide 
nanoparticles. These two methods have been frequently used in the literature since it has been 
established that biological properties vary depending upon the synthesis method (66). TEM 
images of CeO
2
 NPs prepared using water-based or hexamethylenetetramine (HMT) (synthesis 
methods are shown in Supplementary Figure 1. In general, the water-based NPs are smaller and 
rounder than the HMT-based NPs which display a sharp, angular shape. This figure 
demonstrates that depending upon synthesis method and the various conditions during 
synthesis (see Materials and Methods) nanoparticles of the same core cerium oxide 
composition (CeO2) can be very different morphologically yet the biological relevance of these 
differences is poorly understood. 
Physico-Chemical Properties of Cerium Oxide Nanoparticles (CeO
2
) 
Nanoparticles in general exhibit novel surface properties that can affect their chemistry 
and their interaction with biological systems. Supplementary Figure 2 contains a chart outlining 
the physico-chemical characteristics of all CeO2 NPs used throughout this study. Distribution of 
the hydrodynamic radius of individual particles is shown in Supplementary Figure S1A-E. 
Surface charge differences of water-based CNPs (CNP1 and CNP2) were estimated in dH2O 
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suspension. The surface oxidation state (Ce3+/Ce4+ ratio) of the CeO2 NPs preparations were 
calculated from x-ray photoelectron spectroscopy (XPS) data as described previously (157). The 
intensity of peaks at 880.8, 885.8, 899.3 and  903.5 eV corresponding to the cerium (III) 
oxidation state and intensity of peaks at 881.9, 888.4, 897.9, 901.2, 906.8 and 916.3 eV 
corresponding to the cerium (IV) were determined and ratios calculated. Deconvoluted XPS 
spectra for all nanoparticles used in this study are shown in Figure S2A-E. Fourier transform 
infrared spectroscopy (FTIR) spectrum of hexamethyltetramine (HMT) and HMT-CNP1 revealed 
residual HMT on the surface of the HMT-CNP1 as compared with water-based CNP1 (Figure S3). 
The level of the organic was determined to contain HMT and was estimated by calculating 
differential scanning calorimetry - thermogravimetric analysis (DSC-TGA) by the percentage of 
weight loss (158). TGA-plot of thermal decomposition of HMT present on the surface of the 
HMT-based HMT-CNPs is shown in Figure S4A-C.  
  Water-based CeO2 NPs (CNP1 and CNP2) were comprised of a crystalline lattice and due 
to their nanometer length scale, and based on previous reports, oxygen defects at the surface 
are present that yield reactive sites (140). Within these sites, water-based CeO2 NPs have the 
ability to interchange between the 3+ and 4+ oxidation state (55). Two water-based CeO2 NPs 
exhibiting mixed Ce3+/Ce4+valence states were synthesized (81). CeO2 NPs with a  higher 3
+/4+ 
ratio of approximately 1.28 (CNP1) exhibit efficient superoxide dismutase (SOD) activity (55, 
126) when compared to CeO2 NPs with lower 3
+/4+ ratio of approximately 0.37 (CNP2). It should 
be noted that CeO2 NPs with lower 3
+/4+ ratio (CNP2) exhibit increased catalase mimetic 
activity (67) as well as the ability to effectively scavenge soluble nitric oxide (·NO) (68).  HMT-
based CeO2 NPs (HMT-CNP1, HMT-CNP2 or HMT-CNP3) contained lower 3
+/4+ ratios measuring 
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0.37, 0.36, 0.32 respectively, very similar to CNP2, however their catalytic natures towards 
superoxide, hydrogen peroxide or ·NO has not yet been reported. HMT-CNP1 and HMT-CNP3 as 
synthesized contained very similar concentrations of HMT, 1.68 % and 1.78 % HMT respectively 
however, they differ in their shape with HMT-CNP1 morphology as polygonal and HMT-CNP3 
morphology as round (Supplementary Figure 1). HMT-CNP1 differed from HMT-CNP2 in the 
amount of HMT present on the surface of the nanoparticles. In addition, the mean 
hydrodynamic ratios of all three HMT-CNP’s were increased when compared to the two water-
based CNP’s. This becomes important when attempting to understand the biochemical 
properties of NPs in presence of biological molecules such as proteins. The type of biomolecule 
and type of interaction that nanoparticles can participate in can be preferentially affected by 
both size and surface properties of the nanoparticles (159).  
 Nanoparticles have high surface area to volume ratios and the physical properties of a 
nanoparticle can be dominated by the nature of the nanoparticle surface (160). The surface 
areas, as determined by BET, closely ranged between 71 and 118 m2/g and it appears that the 
presence of HMT had no dramatic influence on surface area. Particle size and surface area are 
important features when considering in vivo nano-bio reactivity (161). High surface areas can 
also increase surface reactivity leading to catalytic activities that can be both beneficial and 
detrimental to cells (66). Though consisting of identical core materials, CeO2, the 
physicochemical properties CeO2 nanoparticles produced by different methods can differ 
extensively and have implications that must be thoughtfully considered when adapting them 
for use in biological systems. These material properties can affect how cells respond to 
nanoparticles including whether or not they exhibit toxicity. 
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HMT-based Nanoparticles are More Toxic Than Water-based Cerium Oxide Nanoparticles 
The rapid development of cerium oxide nanoparticles for various applications in many 
years has led to numerous studies evaluating CeO2 NPs toxicity or biocompatibility. We 
employed the primary cell type Human Umbilical Vein Endothelial Cells (HUVECs) as a biological 
model to test toxicity in the context of human tissue. To investigate whether different particles 
made using different synthesis methods can effect overt toxicity, HUVEC cells were exposed to 
increasing CeO2 NPs concentrations (0, 0.02, 0.08, 0.86, 8.6, 17 μg/mL) for 48 h (Figure 15). It 
should be noted that the HMT-CNP NPs were extensively washed during synthesis to avoid 
adsorption of background molecules of HMT onto the NPs so to prevent the residual HMT from 
affecting the NPS surface chemistry or be present in the aqueous portion of the samples (See 
Materials & Methods). We observed a reduced toxicity for CNP1, as previously reported (162) 
(Figure 15A) with similar observations for CNP2 (Figure 15B). Even at the highest concentrations 
(17 μg/mL), CNP1 and CNP2 only had modest effects on cell viability (80 %) whereas HMT-CNP1 
showed a greater reduction in cell viability (70 %). However, at a ten-fold lower concentration 
(0.86 μg/mL) the HMT-CNP1 begin to exhibit a derogatory effect whereas the water-based, 
CNP1 and CNP2 did not (Figure 15C). To address whether the HMT concentration was 
responsible for the deceased cell viability, HMT-CNP2s which contain 8.16 % HMT (Figure 15D) 
were also tested and MTT results are similar to HMT-CNP1 (Figure 15C). Finally, to address if 
shape of the nanoparticle was a factor in toxicity, HMT-CNP3 containing similar concentration 
of HMT as HMT-CNP1 however having a rounder appearance, similar to CNP1 and CNP2 
(Supplementary Figure 1), were tested. MTT results for HMT-CNP3 (Figure 15E) were again 
similar to HMT-CNP1 strongly suggesting that increasing HMT concentration or shape did not 
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play a role in the decreased HUVEC viability of HMT-CNP1 when compared to water-based 
CNP1 and CNP2. Additionally, all three HMT-CNPs started to show decreased cell viability at 
0.86 μg/mL concentration whereas the both CNPs do not exhibit any toxicity at the 0.86 μg/mL 
concentration. To rule out the decreased cell viability was due solely to the presences of the 
HMT solvent, we test the higher concentrations of HMT solvent only and found no toxicity to be 
attributed to the presence of the solvent alone (Figure 15F). The MTT assay relies upon 
metabolically active cells to reduce the MTT dye. Mitochondria are the cell’s source of energy 
by producing adenosine-5'-triphosphate (ATP) through oxidative phosphorylation. This led us to 
determine if intracellular ATP levels of HUVECs exposed to various preparations of CeO2 NPs 
would be affected. 
Exposure to HMT-CNP Leads to Decreases in Intracellular ATP Levels  
To analyze if there was a link between exposure to HMT-CNPs and reduced HUVEC 
viability, we treated HUVECs with increasing CeO2 NPs concentrations (0, 0.02, 0.08, 0.86, 8.6, 
17 μg/mL) and measured ATP levels in cell lysates at 48 h as an alternative to MTT reduction. At 
the higher two exposure concentrations, both CNP1 (Figure 16A) and CNP2 (Figure 16B) had 
diminished ATP levels (85-68%, respectively) as compared to controls. However, HMT-CNP1 
treated cells showed dramatically reduced ATP levels at a ten-fold lower exposure of 0.86 
µg/mL (42 %) Figure 16C). We found similar decreases at the 0.86 μg/mL concentrations using 
HMT-CNP2 (Figure 15D) and HMT-CNP3 (Figure 16E). Similar to our MTT results, HMT solvent 
alone had no effect on ATP concentration. Thus exposure to HMT-CNPs at lower doses resulted 
in a significant reduction in ATP levels than CNP1 or CNP2 exposure.  
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HMT-CNP1 aggregate in exposed HUVEC cells.  Cerium oxide nanoparticles are readily 
internalized by cells due to their small size however to visualize nanoparticles, high resolution 
transmission electron microscopy or a fluorescent tag is normally utilized (46, 98). Since the 
HMT-CNPs all had similar toxicities (Figures 15 & 16) we chose to use HMT-CNP1 for additional 
in depth comparisons with CNP1 and CNP2. Untreated HUVECs as well as CNP1 and CNP2 (8.6 
µg/mL) treated HUVECs exhibited no visible changes (Figure 17A - C). Strikingly, HUVECs treated 
with HMT-CNP1 at the same concentration exhibited visible changes in morphology with bright 
field microscopy (Figure 17D). The addition of a nuclear stain helped us to localize their 
subcellular location and highlight the presumed HMT-CNP1’s aggregation in HUVECs. The ability 
to see nanoparticles using unaided microscopy techniques is uncommon. In the study by Yokel, 
et. al., similar CeO2 NPs agglomerations were seen in light microscope images of spleen of rats 
treated with 250 mg/kg CeO2 NPs after only 1 h (163). These intracellular accumulations do not 
appear to have a specific sub-cellular localization and led us to probe the biological interaction 
of our CeO2 NPs with HUVECs. 
Confocal Laser Scanning Microscopy (CLSM) Images Reveal Perinuclear Aggregation of HMT-
CNP in HUVECs 
It has been reported that CeO2 NPs dispersed directly into cultures media may form 
aggregates on cells (164). To confirm whether the dense granules visualized by bright field 
microscopy were actually HMT-CNP1 aggregates within the cell and not simply associated 
outside the cells, HUVECs were treated for 24 h with nanoparticles, washed repeatedly, 
trypsinized and seeded onto glass coverslips for 4 h (to allow for cell attachment) before 
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fixation. Using immunocytochemistry we labeled the plasma membranes of HUVECs with wheat 
germ agglutinin (WGA) with fluorescein conjugate and took simultaneous fluorescent and 
bright field imaging using confocal microscopy. Untreated, CNP1 and CNP2 (8.6 µg/mL) treated 
HUVECs under bright field and merged channels show no evidence of nanoparticle aggregation 
(Figure 18A & B). By contrast, HUVECs treated with HMT-CNP1 (8.6 µg/mL) showed a robust 
increase in agglomerated, granular material in both the bright field and merged channels 
(Figure 18D). This aggregation becomes even more evident in HUVECs treated with a higher 
concentration of HMT-CNP1 (86 µg/mL) (Figure 19). Notably, CLSM highly suggested that the 
apparent dense granules were in fact intracellular HMT-CNP1s and their subcellular location 
was peri-nuclear. The subcellular localization is in agreement with previous studies testing CeO2 
NPs using in vitro cell culture models (165). 
HMT-CNP1 are Transported into HUVECs More Efficiently Than Water-based Cerium Oxide 
Nanoparticles 
Uptake of nanomaterial varies vastly between materials tested and cell types (166, 167).  
Based upon the morphological changes in HUVECs treated with HMT-CNP1 easily seen by light 
microscopy, we incubated HUVECs with increasing concentrations (0, 1.7, 8.6, 17, 86 µg/mL) of 
CNP1, CNP2 and HMT-CNP1 and harvested cells after 24 h. We used inductively coupled plasma 
mass spectrometry (ICP-MS) to determine the concentration of cerium inside the cells. 
Interestingly, CNP2 uptake was more efficient than CNP1 uptake and cellular uptake of HMT-
CNP1 was greatly increased in HUVECs at every concentration tested (Figure 20). Taken 
together, this clearly shows that HMT-CNP1s are readily internalized by HUVEC cells and this 
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could be a contributing factor as to the toxicity previously observed in a Caenorhabditis elegans 
model (65). We tested CNP1 and HMT-CNP1 in a comparable model system, Drosophila 
melanogaster and found that CNP1 were not toxic and HMT-CNP1 NPs were only marginally 
toxic at a concentration of 860 µg/mL (Figure 21). Thus, uptake must be taken under 
consideration when determining toxicity. Our data shows that the CNP2 are also readily taken 
up and yet they have not shown toxicity at the same level as HMT-CNP1 in HUVECs. It should be 
noted that CNP2 exhibit catalase mimetic activity and scavenge ·NO (67, 68) and therefore 
these catalytic activities could be at the basis for their lack of toxicity (98). 
CeO
2
 NPs with Increased Surface 4+ Character Exhibit Phosphatase and ATPase Activity  
Phosphorylation and dephosphorylation play significant roles signaling, energy transfer 
and utilization within cells. Phosphate ester hydrolysis of biological molecules by CeO2NPs 
would have important implications in their potential toxicity. In order to test any potential 
phosphatase activity of CNPs and HMT-CNPs, we first used p-nitrophenyl phosphate (pNPP) as a 
screening substrate (168).  This assay uses an artificial chromogenic substrate that is readily 
hydrolysed by phosphatases and allowed us to detect any potential phosphatase mimetic 
activity.  We found that CNP2 as well as HMT-CNP1 were able to de-phosphorylate pNPP 
whereas CNP1 did not (Figure 22A). These results agreed with previous observations for water-
based ceria (168). Our initial results strongly suggested that cerium oxide nanoparticles with 
increased 4+ shared a similar catalytic activity. In order to corroborate the phosphatase 
mimetic activity and possibly explain the mechanism of cell death, we used ATP as the substrate 
and looked at free phosphate production using two different assays. Our results show again 
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that CNP1 did not act as a phosphatase using ATP for the substrate (Figures 22A and 23E). SiO2 
NPs, a metal oxide NP of similar size was used as a negative control and also did not cause the 
release of phosphate (Figure 22A and B). However, CNP2 and HMT-CNP1 did release phosphate 
from ATP with CNP2 showing a robust activity (Figure 22B). To obtain quantitative information 
on the effect of CNP2 and HMT-CNP1, we determined the apparent Km. Experimentally, we 
followed the kinetics of Pi released in a continuous reaction and determined the initial rates of 
free phosphate release from 34 µg/mL NPs in the presence of increasing concentrations of ATP 
(Figure 23A-D). The apparent Km for HMT-CNP1 was 39.9 ± 8.2 µM. CNP2 were efficient 
phosphatases at lower substrate concentrations however when approaching physiological 
concentrations of ATP, CNP2s reached saturation and rates declined however CNP2 apparent 
Km was determined to be 48.4 ± 10.6 µM. We compared the kinetic behavior of CeO2 NPs with 
an established, physiologically relevant ATPase, dynein ATPase which has reported Km of 20 μM 
(169). We chose to compare to a motor protein since they have multiple active sites (170), 
which is similar to nanoparticles having numerous engineered vacancies for  reactions to occur. 
In addition, dynein ATPase is located in the cytoplasm, along the same location as we saw the 
aggregation of HMT-CNP1 NPs (Figures 17 and 18). However, CeO2 NPs differ from dynein 
ATPase in terms of turnover rate. Dynein APTase Vmax is 0.22 μM/s (169) however the Vmax 
values for CNP2 and HMT-CNP1 were 0.017 nmol/ min and 0.024 nmol/min (respectively). 
Collectively, these results suggest that CeO2 NPs with increased level of 4+, regardless of their 
synthesis method, are competent phosphatases. They were able to hydrolyze various 
substrates including pNPP (Figure 22A), ATP (Figure 22B and Figure 23A-D) and GTP (data not 
shown). However, HMT-CNP1 is more readily taken up by cells so the concentration of the 
78 
 
catalyst is higher in cells than those exposed to CNP2. The combination of uptake and catalytic 
activity must be considered when determining toxicity. 
Synthesis Method Determines Surface Catalytic Character of CeO
2
 NPs  
Having identified ATPase as a critical catalytic character for HMT-CNPs in terms of 
toxicity, we tested these preparations of CeO2 NPs to assess the effect of synthesis on their 
catalytic activity at a broader level. To evaluate the potential catalytic activities we tested HMT-
CNP1s for their ability to scavenge ·NO or to act as SOD or catalase mimetics. Unlike CNP1 or 
CNP2, HMT-CNP1s did not show any reactivity ·NO (Figure 24A), superoxide (Figure 24C), and 
hydrogen peroxide (Figure 24D).  
Reduction of Ce4+ to Ce3+ causes oxygen vacancies or defects on the surface of the 
crystalline lattice structure of the particles, generating a cage for redox reactions to occur (125). 
It has been established that the specificity of some of the catalytic activities depend upon the 
ratio of Ce3+/Ce4+ (68, 94). Table 2 chart highlights water-based synthesis method of CeO2 NPs 
leads to unique physical and catalytic characteristics that are not found in CeO2 NPs synthesized 
by HMT-based method. In addition, these catalytic activities seem to correlate with the 3+/4+ 
ratio, specifically NPs with more Ce4+ displaying phosphatase activity. This reiterates the need 
for the careful characterization of nanoparticle preparations and a thorough understanding of 
their catalytic activities.  
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Discussion 
The toxicology and surface reactivity of CeO2 nanoparticles synthesized by two different 
methods were compared in this work in order to elucidate the mechanisms behind the varied 
observations with biological models in the current literature. Due to the small size of NPs, TEM 
is an appropriate technique to use for visualizing NPs inside cells, since light microscopy fails to 
resolve NPs at a single particle level (171). However, HMT-CNP1 are readily taken up by HUVECs 
and their aggregation was visible using conventional light microscopy techniques (Figures 5 and 
6). An increase in the uptake of HMT-CNP1 certainly could have a negative effect on a HUVEC 
cell’s metabolism. The increased uptake may be due to electrostatic interactions, given the fact 
that the zeta potential of HMT1 and CNP2 are more positive than CNP1 (Figure 2.) A positively 
charged particles would more readily be taken up by a negatively charged cell. We also 
observed significant aggregation of HMT-CNP1 in intracellular vesicles in HUVEC cells (Figures 
5& 6). It has been reported that, under hydrothermal conditions, HMT can promote the 
formation of well-aligned and highly crystallized ZnO nanorods and nanowires when a ZnO seed 
layer was adopted (172). So, it is certainly possible that similar nucleation events may exist in 
our current HMT-CNP system as well. However, the CNP2 are also readily taken up but do not 
aggregate (Figures 5 & 6) and yet they do not show the level of toxicity that the HMT-CNP1 
demonstrated. CNP2, though also taken up by HUVECS (Figure 7), also are catalase mimetics 
(67) and scavenge soluble ·NO (68). Therefore CNP2s may reduce the level of H2O2 as well 
reduce the downstream damage caused by excessive ·NO.  Peroxynitrite (ONOO-), formed by 
the diffusion limited inter-action of superoxide (O2
·-) with ·NO, is a potent oxidant that can lead 
to the detrimental, 3-nitrotyrosine, post-translational modification of tyrosine residues in 
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proteins (34) as well oxidize lipids and DNA. There are efficient cellular means reduce both O2
·- 
and ·NO during normal cellular metabolism however in a diseased state, an imbalance can 
occur due leading to the cells inability to remove excess O2
·- and ·NO. Therefore, decreasing the 
precursors of the strong oxidizer ONOO- would reduce tissue damage in all the major 
biomolecules. It should be noted that when cells are cultured in 21 % O2, cells in culture are 
generally seen as being under constant oxidative stress (173).  
The intercellular location of the HMT-CNP1 may also play a role in their toxic nature. We 
found the HMT-CNP1 aggregated in a peri-nuclear location (Figure 5) aligning with the 
endoplasmic reticulum (ER) as visualized by wheat germ agglutinin (WGA) antibody (Figure 6). 
Since this antibody labels glycoproteins, we see an increase of signal from the ER and Golgi, the 
location in the cells where sugars are incorporated into proteins in cells, in all cell images. 
Disrupted energy metabolism leads to increased ROS and therefore increased free radicals and 
the resulting downstream damage of protein modification, lipid peroxidation and DNA damage  
(174). The peri-nuclear location of the HMT-CNP1s may interfere with normal cellular 
processes, such as protein post-translational modifications (i.e. phosphate) or energy 
metabolism, leading to adverse cellular responses. In addition to the location of HMT-CNP1 
affecting the cell, their catalytic ATPase ability would have a further negative affect on cell 
survival due to decreased ATP levels. This two-fold hit on cells by HMT-CNP1 might explain the 
drastic difference in toxicity as compared to CNP1 or CNP2. 
Nanoparticles in general exhibit novel surface properties that can affect their chemistry 
and their interaction with biological systems. In addition, we have demonstrated that synthesis 
methods of CeO2 NPs can further affect surface properties. For non-redox active 
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nanoparticles, varying the synthesis procedure may not have a substantial effect but our data 
demonstrates that it is not the case when dealing with redox active nanomaterials. A slight 
change in physico-chemical properties (Figure 2) can give you a vast difference in the redox 
properties of the nanomaterials (Figure 9). During the synthesis of water-based CeO2 NPs, 
oxygen vacancies are created at the surface yielding reactive sites. Within these sites, CeO2 NPs 
have the ability to interchange between the 3+ and 4+ oxidation state (55). The cerium atoms 
on the surface of these vacancies are in the 3+ state (125). Kuchma et. al. report that the 
phosphatase activity appears to be dependent upon the Cerium(III) sites (168). It is possible 
that the ATPase activity seen in the CNP2 and HMT-CNP1 may be due to a nucleophile 
attraction of the Ce3+ and the terminal phosphate on an ATP molecule. Paradoxically, CNP1, 
which have more vacancies on the surface are not phosphatases. Additionally, there are 
phosphate esters on the backbone of nucleic acids. It is known that lanthanide ions effectively 
hydrolyze DNA and RNA (175) with CeIV ions being the most active for DNA (176).  We tested if 
CeO2 NPs with varying ratios of Ce
3+/Ce4+ would be able to hydrolyze other types of phosphate 
bonds. We exposed DNA to increasing concentrations of CNP1, CNP2 and HMT-CNP1 ranging 
from 0, 86, 172, 430 μg/mL at both room temperature and 37° C. There was no apparent 
change in the sizes of the DNA (Supplementary Figure 3).  Although CNP2 and HMT-CNP1s act 
as phosphatase mimetics, the phosphate diester groups on DNA remains intact in the presence 
of these NPs and therefore CeO2 NPs are not nuclease mimetics. CeO2 NPs exhibit specificity 
towards phosphate ester linkages and the mechanism of hydrolysis will need to be 
experimentally determined to understand this apparent specificity. 
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The study of the chemical and biological properties of CeO2 NPs has expanded recently. 
Although most of the focus has been on the ability of these materials to reduce reactive oxygen 
and nitrogen species in biological systems (46), there are reports that claim that nanoceria are 
toxic. Unfortunately, the material synthesis methods used are not always significantly reported 
and it is likely that these observed toxicities are the result in the variations of synthesis 
methods. The CeO2 NPs synthesized in HMT resulted in different surface chemistry which 
resulted in different catalytic activities than the water-based NPs. The increased uptake and 
phosphatase/ATPase activity of HMT-CNP1 may underlie their toxicity. With the recent 
burgeoning growth of the use of CeO2 NPs as potential therapeutics, synthesis method and 
surface chemistries must be emphasized. 
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Figures and Tables 
 
Figure 15: Cell viability of HUVECs exposed to various preparations of CeO2 NPs. 
HUVEC cells were exposed to increasing CeO2 NPs concentrations (0, 0.02, 0.08, 0.86, 8.6, 17 
μg/mL). A) CNP1. B) CNP2. C) HMT-CNP1. D) HMT-CNP2. E) HMT-CNP3. Cell viability was 
determined by dividing the absorbance of treated samples to untreated controls and reported 
as a percentage of control cells. The mean of at least 4 independent cultures is plotted with 
standard deviation as error.  
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Figure 16: Intercellular ATP levels of HUVECs exposed to various preparations of CeO2 NPs. 
HUVEC cells were exposed to increasing CeO2 NPs concentrations (0.02, 0.08, 0.86, 8.6 17 
μg/mL). A) CNP1. B) CNP2. C) HMT-CNP1. D) HMT-CNP2. E) HMT-CNP3. ATP level was 
determined by dividing the luminescence of treated samples to untreated controls and 
reported as a percentage of control cells. The mean of at least 4 independent cultures is plotted 
with standard deviation as error. *, p ≤ 0.05, #, p ≤ 0.001. 
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Figure 17: Live cell examination of HUVEC cells exposed to HMT-CNP1. 
HUVEC cells were exposed to 8.6 μg/mL CeO2 NPs for 20 h. A) Control cells. B) CNP1. C) CNP2. 
D) HMT-CNP1. Hoescht dye was added just before imaging to show location of nuclei. 
Representative images feature 4x zoom of region of interest. Scale bar = 50 μm. 
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Figure 18: Intracellular aggregation of HMT-CNP1 as viewed by confocal laser scanning 
microscopy (CLSM). 
Cells were exposed to nanoparticles for 24 h, washed, trypsinized and seeded onto glass 
coverslips for 4 h (to allow for attachment), fixed and labeled with antibody for identification of 
plasma membranes (green channel) and Hoechst 33342 (blue channel) for identification of 
nuclei. A) Control/no treatment B) 86 μg/mL CNP1 C) 86 μg/mL CNP2 D) 86 μg/mL HMT-CNP1. 
Scale bar = 50 μM. Asterisk follows representative region of HMT-CNP1 aggregation. 
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Figure 19: CLSM images of HUVECs showing intracellular aggregation after exposure to 86 
μg/mL HMT-CNP1. 
Cells were treated for 24 h with nanoparticles, washed, trypsinized and seeded onto glass 
coverslips for 4 h (to allow for attachment), fixed and then labeled with WGA for identification 
of plasma membranes (green channel) and Hoechst 33342 (blue channel) for identification of 
nuclei. A) 86 μg/mL HMT-CNP1. B) Control/no treatment. Scale bar = 50 μM.  
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Figure 20: Increased uptake of HMT-CNP1 as measured by ICP-MS. 
HUVEC cells were incubated with various CeO2 NPs for 24 h, washed two-times to remove 
extracellular nanoparticles, collected by typsination and washed with PBS again to remove 
excess media and particles which may be adsorbed on the surface of the cells. The 
concentration of cerium inside cells was measured by ICP-MS as described in methods.  
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Figure 21: Exposure of Drosophila melanogaster to CeO2 NPs does not significantly alter 
development. 
Oregon-R (OR) wild-type larvae were fed JazzMix® supplemented with 86 μg/mL of CeO2 NPs or 
appropriate solvent control. Wild-type larvae survival to reach pupariation was tabulated. 
Minimum 50 larvae per condition per experiment. p=0.069 by One way ANOVA followed by 
Tukey Post Hoc Tests. 
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Figure 22: p-nitrophenyl phosphate (pNPP) and ATP hydrolysis by various preparations of 
CeO2 NPs. 
(A) 34.4 μg/mL CeO2 NPs were incubated with pNPP and conversion to p-nitrophenyl was 
measured by following its absorbance at 405 nm. (B) Free phosphate released by NPs was 
quantified by malachite green assay using 200 μM ATP as substrate comparing 34.4 μg/mL of  
indicated nanoparticles in 50 mM Tris buffer at pH 8.0. Traces were recorded using Spectra Max 
190 spectrophotometer. Graphs are representative of 3 or experiments.  
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Figure 23: CNP2 and HMT-CNP1s exhibit significant ATPase activity at physiological relevant 
concentrations of ATP. 
ATPase activity of CeO2 NPs was quantified by measuring phosphate released with EnzCheck® 
phosphate assay using varying concentrations of ATP with 34 μg/mL NPs. (A) CNP2 (B) HMT-
CNP1 (E) CNP1. Line plot is representative of 3 or more experiments. Double reciprocal plots of 
ATPase activity of (C) CNP2 and (D) HMT-CNP1, with ATP as substrate while keeping constant 
the concentration of NPs (34 μg/mL).  
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Figure 24: CNP-HMT1 do not exhibit the ·NO scavenging, SOD mimetic or catalase mimetic of 
CNP1 and CNP2. 
A&B) Fluorescence emission was monitored at 530 nm upon excitation at 503 nm in the 
presence of the ∙NO generator, 100 μM DEA/NO (Dowding et.al., ChemComm2012). A) 
Scavenging of ·NO in presence of HMT-CNP1 at concentrations indicated. B) Scavenging of ·NO 
in the presence of 100 μM Glutathione (GSH). C) Ferricytochrome C reduction was followed 
spectroscopically by measuring increase in absorbance at 550 nm (Korvics et. al., ChemComm 
2007). SOD = superoxide dismutase. D&E) Hydrogen peroxide concentration was followed by 
changes in absorbance of the reaction monitoring absorbance at 240 nm (Pirmohamed et. al., 
ChemComm 2010). D) Reduction of H2O2 concentration in the presence of HMT-CNP1.  E) 
Reduction of H2O2 concentration in the presence of CNP2. Graphs are representative of 3 or 
more experiments.  
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Table 2: Synthesis method determines surface character and catalytic activities of CeO2 NPs. 
Catalytic 
activity 
Assay CNP1 CNP2 HMT-
CNP1 
SiO
2
 
Phosphatase pNPP no yes yes no 
ATPase 
  
Malachite Green no yes yes no  
ENZCheck no yes yes n/d  
·NO 
Scavenger 
CuFl assay no  (68) yes (68) no no (68) 
Catalase 
Mimetic 
UV-visible no (177) yes (177) no no 
SOD Mimetic Cytochrome C yes (56) no (56) no no 
Various properties of CeO2 NPs have been tested for their ability to exhibit SOD mimetic, 
catalase mimetic, ·NO scavenging, phosphatase or ATPase activities.  
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Supplementary Figure 1: Size, shape, and morphology variation of Cerium Oxide 
Nanoparticles (CeO2) NPs synthesized by two different synthesis methods. 
TEM images of CeO2 NPs prepared using water-based (A & B) or solvent HMT (C – E) synthesis 
methods.  A) CNP1. B) CNP2. C) HMT-CNP1. D) HMT-CNP2. E) HMT-CNP3.  
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Supplementary Figure 2: Physico-chemical properties of cerium oxide nanoparticles (CeO2) 
prepared by water-based or HMT-based method. 
 
 
Particle
Characteristics CNP1 CNP2 HMT-CNP1 HMT-CNP2 HMT-CNP3
Morphology round round polygonal polygonal round
Crystalline property crystalline 
fluorite 
structure
crystalline 
fluorite 
structure
crystalline 
fluorite 
structure
crystalline 
fluorite 
structure
crystalline 
fluorite 
structure
Size (TEM)
(nm)
3-5 5-8 10-15 10-15 8-10
Hydrodynamic radii 
(nm)
30.84 ±2.8 69.26 ±4.5 147.70  ±6.4 83.56 ±3.2 129.20 ±4.1
Zeta potential 
(mV)
18.6 ±0.6 30.2 ±1.5 34.6 ±1.7 38.6 ±2.3 36.7 ±2.1
Hexamethyltetramine
(% wt)
- - 1.68 ±0.2 8.16 ±0.7 1.78 0.3
Surface Ce3+/Ce4+
ratio
1.28 0.37 0.37 0.36 0.32
BET 
(m2/g)
92 102 86 71 118
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